Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
05/2010 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions May archived by USPTO category 05/10

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
05/27/2010 > patent applications in patent subcategories. archived by USPTO category

20100130401 - Protein hydrolysate and plant sterol containing composition for improving serum lipid profile and preventing atheroscleroris: The invention relates to a terapeutical composition comprising a protein hydrolysate and a plant sterol, wherein the weight ratio of the plant sterol to the protein hydrolysate is from 1:0.02 to 1:150. The invention also relates to a terapeutical composition comprising a protein hydrolysate and a synthetic emulsifier and/or a... Agent: Arent Fox LLP

20100130402 - Biomarkers for insulin resistance and beta-cell dysfunction: The invention provides compositions and methods for determining insulin resistance and/or pancreatic β-cell dysfunction in a subject. The invention also provides compositions and methods for treating a subject according to the insulin resistance and/or pancreatic β-cell dysfunction in the subject.... Agent: Morgan, Lewis & Bockius, LLP (sf)

20100130404 - Biomarkers for cardiodiabetes: The invention provides compositions and methods for determining cardiodiabetes status in a subject. The invention also provides compositions and methods for treating a subject experiencing cardiodiabetes.... Agent: Morgan, Lewis & Bockius, LLP (sf)

20100130403 - Biomarkers for insulin efficacy: The invention provides compositions and methods for determining insulin efficacy in a subject. The invention also provides compositions and methods for treating a subject according to the efficacy of insulin in the subject.... Agent: Morgan, Lewis & Bockius, LLP (sf)

20100130405 - Biglycan and related therapeutics and methods of use: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those... Agent: Ropes & Gray LLP

20100130407 - Facilitation of resuscitation from cardiac arrest by erythropoietin: The present invention relates generally to the use of erythropoietin (EPO) to facilitate resuscitation from cardiac arrest. For a mammalian subject suffering from cardiac arrest, concurrent administration of EPO with resuscitation after the onset of ventricular fibrillation facilitates the resuscitation. Administration of EPO serves to attenuate myocardial abnormalities caused by... Agent: Joseph A. Fuchs Rockey, Depke & Lyons, LLC

20100130406 - Glycated milk and uses thereof: Milk-based products and drinks are provided including specified forms of identified proteins or fragments thereof, as are methods for the use of such milk-based products and drinks in the promotion of sleep.... Agent: Greer, Burns & Crain

20100130409 - Cyclic peptide cxcr4 antagonists: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.... Agent: Eli Lilly & Company

20100130408 - Use of modified cyclosporins: Disclosed are non-immunosuppressive cyclophilin-binding cyclosporine having useful properties in the prevention or treatment of liver diseases.... Agent: Novartis Corporate Intellectual Property

20100130419 - Artery- and vein-specific proteins and uses therefor: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a... Agent: Ropes & Gray LLP

20100130421 - Biomodulators for treatment or prevention of disease: The invention provides methods and compositions for the treatment or prevention of animal disease whereby the compositions are biomodulators of plant physiological activity. Inventive methods include administration of one or more biomodulators to an animal such as human for the treatment of cell proliferation or differentiation diseases such as cancer.... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20100130426 - Compositions containing satiogens and methods of use: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100130412 - Compositions to prevent and treat type-1 diabetes: The present invention is based on the discovery that Humanin and humanin analogues protect pancreatic beta cells in vitro and in vivo from apoptosis. Accordingly, humanin and its analogues are useful for preventing and treating diabetes and promoting beta cell survival in a number of applications.... Agent: Townsend And Townsend And Crew, LLP

20100130424 - Crhr2 peptide agonists and uses thereof: The present invention relates to novel peptides that are selective corticotrophin releasing hormone receptor type 2 (CRHR2) agonists and compositions thereof for the treatment, amelioration or inhibition of cardiovascular conditions, including but not limited to heart failure. The novel peptide agonist preferably comprise modifications that include pegylated peptides. Furthermore, the... Agent: Philip S. Johnson Johnson & Johnson

20100130411 - Method for treating cartilage disorders: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of... Agent: Arnold & Porter LLP (24126) Attn:IPDocketing Dept.

20100130414 - Methods of using e2f2 for the treatment of hypertension: The present invention features compositions and methods of treating or preventing hypertension or a cardiac indication. In particular embodiments, the invention provides E2F2 as a new therapeutic target for the treatment of hypertension or a cardiac indication, and methods of increasing the expression and/or activity of E2F2.... Agent: Edwards Angell Palmer & Dodge LLP

20100130416 - Modulation of angiogenesis by a-beta peptide fragments: Provided are Aβ peptide fragments that are useful in inhibiting angiogenesis. Also provided are methods for the treatment of pathological or unwanted angiogenesis and conditions and diseases associated therewith by administering an effective amount of an Aβ fragment. In a particular embodiment, the peptide fragment includes the sequence HHQKLVFF.... Agent: Senniger Powers LLP

20100130410 - Neural regeneration peptides and methods for their use: Embodiments of this invention include novel peptides that can promote survival of neurons and other cell types. Other embodiments of this invention include the methods for the use of peptides to promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation, neuronal survival and/or trophoblast proliferation, trophoblast migration and trophoblase survival.... Agent: Borson Law Group, PC

20100130420 - Novel chimeric ligand-gated ion channels and methods of use thereof: The present invention provides novel chimeric receptors that have unique pharmacology. In particular, the chimeric receptors comprise a mutated ligand binding domain of the α7 nicotinic acetylcholine receptor fused to a transmembrane or channel domain from a ligand-gated ion channel protein. The mutations in the ligand binding domain confer selective... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20100130418 - P2x7 inhibition of epithelial cancers and papillomas: The present invention demonstrates that P2X7 receptor induced apoptosis may be specific for cancerous cells. Treatment with the P2X7 ligand BzATP, increased cellular apoptosis with no associated inflammatory changes or abnormal skin or systemic effects. In mice treated with DMBA/TPA, BzATP decreased papilloma skin formation. BzATP also induced involution of... Agent: Medlen & Carroll, LLP

20100130428 - Polymer factor ix moiety conjugates: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the... Agent: King & Spalding LLP

20100130427 - Polymer-factor viii moiety conjugates: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.... Agent: King & Spalding LLP

20100130415 - Stem cell secreted product derived compositions for wound treatment: Compositions including formulations comprising secreted products obtained from the culture medium of stem cells, such as umbilical cord blood stem cells, or embryonic germ cell derivatives, or embryonic stem cells, are provided for enhancement of wound healing. Further compositions contain components identified in such culture medium to enhance wound healing.... Agent: Howrey LLP-hn

20100130417 - Transforming growth factor alpha hii: The present invention discloses transforming growth factor alpha HII polypeptides and polynucleotides encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and therapeutic uses of the polypeptides which include stimulating wound healing, treating neurological disorders, treating ocular disorders, treating kidney and liver disorders, and... Agent: Arnold & Porter LLP (24126) Attn:IPDocketing Dept.

20100130413 - Treatment for age-related macular degeneration and other diseases of the eye: A method is disclosed for treating diseases or disorders of the eye involving undesired neovascularization by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1). The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering a complement... Agent: Leon R. Yankwich

20100130423 - Treatment of myeloproliferative disorders with adaptor protein lnk: Janus kinase 2 (JAK2) associates with cytokine receptors and is essential for signal transduction in hematopoietic cells. The JAK2 mutation, JAK2 V617F, prevalent in myeloproliferative disorders, confers cytokine-independent proliferation and constitutive activation of downstream signaling pathways, when co-expressed with homodimeric type I cytokine receptors. The adaptor protein LnK is a... Agent: Davis Wright Tremaine LLP/los Angeles

20100130422 - Use of cocoa extract: A cocoa extract obtainable by the extraction of non-defatted cocoa beans which have not been fermented or have been allowed to ferment for no more than three days, having a polyphenol content of more than 25% by weight, may be used in the treatment or alleviation of obesity.... Agent: Hoxie & Associates LLC

20100130425 - Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia: Methods of protecting cells against cytotoxic insults are provided. The methods involve administering a composition including a Toll-like receptor (TLR) ligand, for instance a TLR7, TLR8, or TLR9 ligand to a subject. The methods are applicable to the protection of neural and non-neural cells. For example, methods of protecting a... Agent: Klarquist Sparkman, LLP

20100130429 - Bbs10 related diagnostic methods and reagents for bardet-biedl syndrome: The present invention relates to the identification of a gene, designated BBS1O, that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. Methods of use for the gene,... Agent: Foley Hoag, LLP (w/jhv)

20100130430 - Stabilized therapeutic small helical antiviral peptides: Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus in a cell. Also provided are methods of treating a mammal infected with a capsid-containing virus. Further provided are methods of treating... Agent: K&l Gates LLP

20100130431 - Discordant helix stabilization for prevention of amyloid formation: The invention is based on the discovery that the presence of a discordant helix in a protein or peptide is predictive of that protein or peptide's ability to form amyloid. The invention includes methods for detecting discordant helices and methods of screening for compounds that stabilize the α-helix of a... Agent: Wilmerhale/boston

20100130432 - Non-natural amino acids and neurotensin analogues thereof: This invention relates to non-natural desamino amino acid compounds, methods of making, and peptides containing these compounds as their N-terminus moieties. A preferred example is neurotensin (8-13) in which the N terminus is an alpha desamino N,N dimethyl homolysine residue.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100130433 - Casein-derived peptides having anxiolytic activity: The invention relates to peptides and, in particular, heptapeptides derived from milk casein αs1 and having anxiolytic activity. The invention also relates to pharmaceutical and food compositions containing said peptides and to the preparation methods thereof.... Agent: Pepper Hamilton LLP

20100130434 - Hexose compounds to treat cancer: Methods of treating glioblastoma and pancreatic cancer are provided by the administration of a therapeutically effective amount of a hexose compound to a subject in need thereof The subject invention includes methods of treating brain and pancreatic cancer comprising the administration of a therapeutically effective amount of a mannose compound... Agent: NielsenIPLaw LLC

20100130435 - Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm: Screening for a glucokinase-activating substance among rare sugars and providing a composition for treating disordered conditions in association with glucokinase activity, the composition containing the glucokinase-activating substance as the active ingredient. A promoting agent of glucokinase transfer from nucleus to cytoplasm, the promoting agent containing D-psicose and/or D-tagatose as the... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100130436 - Co-administration of ranolazine and cardiac glycosides: The present invention relates to a method for reducing the toxicity of cardiac glycosides comprising the coadministration of a therapeutically effective amount of cardiac glycoside and a therapeutically effective amount ranolazine. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20100130437 - Topical antibiotic composition for the prevention of lyme disease: A topical pharmaceutical composition comprising an antibiotic is useful for the prevention of Lyme disease.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100130590 - Deletion bearing bard1 isoforms and use thereof: The present invention relates to new protein isoforms, use thereof, methods of preparation thereof, methods of detection thereof, antibodies thereof, combination of antibodies thereof, use of these antibodies and combinations thereof and use of antagonists of those isoforms for the treatment of gynaecological cancers.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100130586 - Diagnosis and treatment of t-cell acute lymphoblastic leukemia: The present invention relates to the field of biotechnological means to diagnose or treat T-cell acute lymphoblastic leukaemia. More particularly, the invention relates to methods to diagnose T-cell acute lymphoblastic leukaemia via determining the presence of a duplication of the MYB gene in cells taken from patients. The invention further... Agent: Traskbritt, P.C.

20100130585 - Methods and compositions for investigation and treatment of cancer using a g-protein coupled eicosanoid receptor: In some embodiments, without limitation, the present invention comprises compositions and methods for the investigation and treatment of cancers by directly or indirectly blocking or interfering with the delivery of survival signals in cancer cells via a G protein-coupled receptor, in some embodiments, a 5-oxoETE or 5-HETE receptor. Some embodiments... Agent: Rader, Fishman & Grauer PLLC

20100130587 - Methods of treating cancer using sirna molecules directed against cd24: A method of treating a CD24-related medical condition is disclosed. The method comprises administering to a subject in need thereof at least one siRNA molecule selected from the group consisting of SEQ ID NO: 1 to 4. Pharmaceutical compositions comprising same are also disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100130589 - Modulation of eif4e expression: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20100130591 - Multiple exon skipping compositions for dmd: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.... Agent: Seed Intellectual Property Law Group PLLC

20100130588 - Novel lipid formulations for nucleic acid delivery: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one... Agent: Townsend And Townsend And Crew, LLP

20100130592 - Rna interference mediated inhibition of grb2 associated binding protein (gab2) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of GRB2 associated... Agent: Merck C/o Sirna Therapeutics, Inc.

20100130595 - Antisense oligonucleotides directed against connective tissue growth factor and uses thereof: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.... Agent: Cooper & Dunham, LLP

20100130594 - Cns gene delivery using peripheral administration of aav vectors: The present invention relates to compositions and methods for the delivery of therapeutic proteins to the CNS using recombinant AAV vectors. More specifically, the invention relates to compositions and methods for delivering proteins into the cerebrospinal fluid of mammalian subjects through peripheral administration of AAV vectors. The invention may be... Agent: Nixon & Vanderhye, PC

20100130597 - Dna-pkcs modulates energy regulation and brain function: The invention relates to new functions of the DNA-PKcs gene product in energy metabolism, brain function and physical fitness.... Agent: Nih-ott

20100130593 - Methods and immune modulator nucleic acid compositions for preventing and treating disease: This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly... Agent: Townsend And Townsend And Crew, LLP

20100130596 - Rad51 derived cancer cell specific promoters for targeted anti- cancer therapy: Provided are compositions and methods for inhibiting growth of cancer cells. The method of the invention relates to delivering to cells an effective amount of a composition that contains a polynucleotide having a Rad51 promoter or a polynucleotide having at least 95% similarity to a Rad51 promoter. The Rad51 promoter... Agent: Hodgson Russ LLP The Guaranty Building

20100130438 - Method for increasing oxytocin release in the epidermis: A method for increasing oxytocin release through direct action on the epidermal keratinocytes is provided. The method for increasing oxytocin release in the epidermis includes increasing the calcium ion concentration in the epidermal cells. In the method of the present invention, the increase of the calcium ion concentration in the... Agent: Darby & Darby P.C.

20100130440 - Antiviral nucleosides: Disclosed are nucleosides which are useful in diagnosing and treating viral infections, for example, infections caused by hepatitis B virus (HBV), and herpes viruses including Epstein Barr virus.... Agent: Bozicevic, Field & Francis LLP

20100130439 - Genomic mutation inhibitors that inhibit y family dna polymerases: Modulators of error prone DNA polymerases are provided. Methods of inhibiting genomic mutation to inhibit the emergence of drug resistant target cells are also provided. Screening assays for identifying modulators of error prone DNA polymerases are provided.... Agent: Quine Intellectual Property Law Group, P.C.

20100130441 - Use of vitamin b12 for treatment of mucosal lesions: The present invention relates to the use of the nutrition supplement known as vitamin B12 (cobalamin) to treat or prevent mucosal lesions. It relates particularly to treatment of mucosal lesions and prevention of development of recurrent mucosal lesions by the repeated administration over a period of time of vitamin B12... Agent: Baker Botts L.L.P.

20100130442 - Lung injury treatment: Techniques for lung injury treatment are provided. For example, a technique for treating a lung injury in a patient includes the step of administering a therapeutically effective amount of a sophorolipid to the patient.... Agent: Ryan, Mason & Lewis, LLP

20100130443 - Chitosan derivatives, compositions and related methods of use: Described herein are methods and compositions using chitosan derivatives to treat and/or inhibit acquisition of multiple drug resistance (MDR). Also described herein are methods and compositions using chitosan derivatives in combination with an antibacterial agent to treat a bacterial infection and/or inhibit growth of bacteria, for example, resulting in a... Agent: Lando & Anastasi, LLP

20100130444 - Complexes of prostaglandin derivatives and monosubstituted, charged beta-cyclodextrins: The present invention relates to water-soluble, non-covalent complexes of a group of prostaglandin derivatives including latanoprost and monosubstituted, charged β-cyclodextrins, as well as uses of these complexes in therapeutic compositions that are administered topically for treating intraocular hypertension and glaucoma.... Agent: Richard Voellmy

20100130445 - Film forming dental compositions and related methods: e

20100130446 - Nitrogen-containing five-membered heterocyclic compound:

20100130447 - Inhibitors of kinase activity: The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLT1, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDR1... Agent: Morrison & Foerster LLP

20100130448 - 3',4',5-trimethoxy flavone derivatives as stimulatn of mucus secretion, method for the same, and pharmaceutical composition comprising the same: e

20100130449 - Use of tri-substituted glycerol compounds for the treatment of radiation injuries: The present invention relates to the use of a tri-substituted glycerol compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention and/or treatment of radiation injuries. Furthermore, the invention relates to in vitro corresponding methods for preventing or treating of radiation damage or injury... Agent: K&l Gates LLP

20100130450 - Methods of treating fungal infections: Methods of identifying compounds that potentiate the activity of antifungal agents, potentiators identified by these methods, and methods of using potentiators are disclosed.... Agent: Wilmerhale/boston

20100130451 - Synthesis of tetracyclines and analogues thereof: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines... Agent: Harvard University & Medical School C/o Wolf, Greenfield & Sacks, P.C.

20100130452 - Use of doxycycline in the treatment of idiopathic pulmonary fibrosis: Use of doxycycline, a non specific matrix metalloproteinase inhibitor, for treatment of idiopathic pulmonary fibrosis and a pharmaceutical composition comprising doxycycline or its congener in combination with another compound selected from the drug listed for treatment of idiopathic pulmonary fibrosis in a standard dose.... Agent: The Webb Law Firm, P.C.

20100130453 - Use of folates for the prevention and treatment of vascular diseases: This invention relates to the use of folates for the prevention and/or treatment of cardiovascular diseases, such as atherosclerosis, and in particular for modulating endothelial nitric oxide synthase (eNOS). The invention further relates to pharmaceutical preparations consisting of said folates and a pharmaceutically acceptable carrier, optionally in combination with other... Agent: Millen, White, Zelano & Branigan, P.C.

20100130454 - 9,10-secopregnane derivatives and medicine: A novel useful vitamin D3 derivative which is reduced in influence on systemic calcium metabolism while retaining excellent vitamin D3 activity. The derivative is a 9,10-secopregnane derivative represented by the following general formula [1]. Also provided is a medicinal composition containing the derivative as an active ingredient. In the general... Agent: Darby & Darby P.C.

20100130455 - Bismethylene-17a carbolactones and related uses: Described herein are bismethylene-17α carbolactone derivatives having progestational and/or antimineralocorticoid and/or aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds.... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20100130456 - Drug combination and its use in the treatment of muscle loss: The present invention is a product comprising a β2 agonist and a progestin, as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of muscle loss. The present invention is also a β2 agonist selected from R,R-formoterol, indacaterol or ritodrine, for use in the treatment... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100130457 - Phenothiazine derivatives for treatment of asthma: The present invention relates to decreasing inflammation and airway obstruction in asthma. The invention also provides compositions and methods of reducing allergic reactions associated with asthma.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100130458 - Polymorphs of fluticasone furoate and process for preparation thereof: Provided are polymorphs of fluticasone furoate and processes for preparation thereof.... Agent: Kenyon & Kenyon LLP

20100130459 - Neuroprotective 7-beta-hydroxysteroids: 3-Hydroxy-7β-hydroxy steroids and 3-oxo-7β-hydroxy steroids and pharmaceutically acceptable estors thereof are useful for protection against neuronal damage.... Agent: Dechert LLP

20100130460 - Topical glucocorticosteroid formulations: Disclosed are topical formulations comprising an androstane steroid, propylene glycol, and benzyl alcohol in an amount effective to dissolve the androstane steroid compound, wherein the amount of benzyl alcohol is not effective to act as a penetration enhancer. The formulations are useful for the treatment of inflammatory and/or pruritic manifestations... Agent: Schwegman, Lundberg & Woessner, P.A.

20100130461 - Pharmaceutical composition for topical application: A topical composition for treatment of contact dermatitis comprising a corticosteroid, one or more drying agents, such as zinc oxide and talc, an alcohol solvent, a humectant and a viscosity agent, such as bentonite. The humectant may be glycerin, and the carrier is water.... Agent: Keaty Law Firm, LLC

20100130463 - 6-substituted estradiol derivatives and methods of use: t

20100130462 - Lanolin compositions and methods for making and using same: A composition suitable for application to the skin comprising lanolin, an oil, an anti-oxidant, and a combination thereof. The composition is suitable for particular application to a human breast.... Agent: Michael Best & Friedrich LLP

20100130467 - Triazolotriazines as kinase inhibitors: The present invention is directed to [1,2,4]triazolo[4,3-b][1,2,4]triazines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.... Agent: Fish & Richardson PC

20100130465 - 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors: The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury,... Agent: Merck Patent Department (k-6-1, 1990)

20100130464 - Pharmaceutical compounds: The invention provides compounds of the formula (I) having ROCK kinase and/or protein kinase p70S6K inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a... Agent: Heslin Rothenberg Farley & Mesiti PC

20100130466 - Triazolyl aminopyrimidine compounds: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.... Agent: Eli Lilly & Company

20100130469 - 2, 6-naphthridine derivatives: The present invention relates to novel organic compounds comprising a naphthyridine which may be mediators of a selective subset of kinases belonging to the AGC kinase family, such as for example PKC, PKD, PKN-1/2, CDK-9, MRCK-beat, PASK, PRKX, ROCK-I/II or mediators of other kinases, the selectivity of which would be... Agent: Novartis Institutes For Biomedical Research, Inc.

20100130468 - Indole carboxamides as ikk2 inhibitors: The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100130470 - Acrylamide derivatives as fab i inhibitors: In part, the present invention is directed to antibacterial compounds.... Agent: Goodwin Procter LLP Patent Administrator

20100130471 - Renin inhibitors: Described are compounds which bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100130472 - Bile acid recycling inhibitors for treatment of obesity and diabetes: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100130474 - Alpha7 nicotinic acetylcholine receptor inhibitors: The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.... Agent: Choate, Hall & Stewart LLP

20100130473 - Compounds: Compounds of formula (I): A-B—C and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein: B is selected from the group consisting of formula (i) where RN is H or Me; or B is a divalent C5 heterocyclic residue containing one or two ring heteroatoms; A is formula (ii)... Agent: Morgan Lewis & Bockius LLP

20100130475 - Preventive or therapeutic agent for inflammatory bowel diseases: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel diseases, which comprises 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzoazepine, a prodrug thereof, preferably 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzoazepine as a prodrug, or a pharmaceutically acceptable salt thereof. The pharmaceutical composition according to the present invention is effective in the prophylaxis and therapy of the inflammatory... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100130476 - Compounds that induce pancreatic beta-cell expansion: The present invention relates to compounds and compositions for inducing the expansion of pancreatic β-cells. The invention further relates to a use of these expanded pancreatic β-cells to reversibly expand pancreatic β-cells and other quiescent cells to overcome deficits associated with degenerative and/or autoimmune diseases.... Agent: Townsend And Townsend And Crew, LLP

20100130477 - Spirocyclobutyl piperidine derivatives: Disclosed herein is at least one spirocyclobutyl piperidine derivative, at least one pharmaceutical composition comprising at least one spirocyclobutyl piperidine derivative disclosed herein, and at least one method of using at least one spirocyclobutyl piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100130481 - Anticonvulsant and anxiolytic methods of using receptor subtype selective agents: Methods of using orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anticonvulsant and anxiolytic activity with reduced sedative, hypnotic, muscle relaxant, or ataxic effects.... Agent: Wisys Technology Foundation, Inc. C/o Mirick, O'connell, Demallie & Lougee, LLP

20100130480 - Benzoquinoline inhibitors of vesicular monoamine transporter 2: The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100130479 - Gabaergic agents to treat memory deficits: The present invention provides molecules and methods for the prevention and/or treatment of memory deficit related conditions and/or enhancement of cognition. In a preferred embodiment, the invention includes compounds, salts and prodrugs thereof for the prevention and/or treatment of these conditions.... Agent: Boyle Fredrickson S.c.

20100130478 - Sustained release formulations of psychoactive drugs: This invention provides biodegradable, sustained-release pharmaceutical compositions of a psychoactive drug formulated with biocompatible, biodegradable tyrosine-derived polyarylates.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20100130482 - Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands: This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of... Agent: Birch Stewart Kolasch & Birch

20100130483 - Novel diazabicyclic aryl derivatives: This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of... Agent: Birch Stewart Kolasch & Birch

20100130484 - Novel bicyclic sulfonamide derivatives which are l-cpt1 inhibitors: i

20100130485 - Cyclopropyl amines as modulators of the histamine h3 receptor: Certain cyclopropyl amines are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20100130486 - Cyclic amine substituted pyrimidinediamines as pkc inhibitors: The invention encompasses compounds having formula I or II and the compositions and methods using these compounds in the treatment of conditions in which inhibition of PKC and PKD is therapeutically useful.... Agent: Rigel Pharmaceuticals, Inc. Bozicevic, Field & Francis LLP

20100130487 - Spiro-oxindole compounds and their uses as therapeutic agents: wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions,... Agent: SeedIPLaw Group PLLC

20100130489 - Imidazolo-heteroaryl derivatives with antibacterial properties: The invention relates to Imidazolo-heteroaryl derivatives of formula (I). The compounds inhibit the activity of the Dlta enzyme of Gram-positive bacteria and are useful to treat Gram-positive bacterial infections. Furthermore the application discloses method for assessing the Dlta inhibitory activity of tested molecules and a method for measuring the efficacy... Agent: Nixon & Vanderhye, PC

20100130488 - Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators: A compound according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R6, R7 and Z are as defined in the specification; pharmaceutical compositions thereof; and methods of use thereof.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20100130490 - Csf-1r inhibitors,compositions, and methods of use: Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at... Agent: Novartis Institutes For Biomedical Research, Inc.

20100130491 - 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators: n

20100130492 - Morpholinopurine derivatives:

20100130493 - Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP

20100130494 - Dermatitis treating agent (as amended): or a group represented by the formula: ═N—, Ring A represents a saturated or unsaturated bicyclic nitrogen-containing heterocyclic group having 1 to 4 substituents selected from hydroxyl group, oxo group, a lower alkoxy group, a di-lower alkylaminophenyl group, a pyperidino-lower alkoxy group, a morpholino-lower alkoxy group, a cyclo-lower alkylamino-lower alkylamino... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100130495 - Compounds 563: The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100130496 - Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase: wherein R1, R2, and Y have any of the values defined herein; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune... Agent: Viksnins Harris & Padys Pllp

20100130497 - Therapeutic compounds: Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity; or derivatives thereof, analogues thereof, pharmaceutically acceptable salts thereof, and metabolites thereof; with the proviso that the compound is not Tranilast.... Agent: Wolf Greenfield & Sacks, P.C.

20100130498 - Agonists of bitter taste receptors and uses thereof: The present invention relates to agonists of the human bitter-taste receptors hTAS2R14, hTAS2R10 and hTAS2R4 and their role in bitter taste transduction. The invention also relates to methods for identifying molecules that modulate, e.g. suppress, or enhance hTAS2R14, hTAS2R10 and hTAS2R4 bitter taste transduction or bitter taste response.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100130499 - Bicycloheteroaryl compounds and their use as trpv1 ligands: and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount... Agent: Dechert LLP

20100130504 - Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to... Agent: Merck

20100130502 - Compounds, formulations, and methods for treating or preventing inflammatory skin disorders: wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms... Agent: Hoffmann & Baron, LLP

20100130500 - Methods and compositions for the treatment of pulmonary hypertension of the newborn: The present invention is directed to a novel methods and compositions for the therapeutic intervention in persistent pulmonary hypertension of the newborn (PPHN). More specifically, the specification describes methods and compositions for treating various types of PPHN using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are... Agent: Marshall, Gerstein & Borun LLP

20100130503 - New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone hsp 90: e

20100130501 - Novel 3-amino-pyrrolo[3,4-c]pyrazole-5(1h, 4h, 6h) carbaldehyde derivatives: The present invention relates to compounds and pharmaceutically acceptable salts of Formulas A and B: (A) and (B) wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts... Agent: Pfizer Inc

20100130505 - Compositions and methods for inhibiting g protein signaling: Disclosed are compositions and methods for treating diseases associated with G protein βγ subunit activity.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100130506 - Organic compounds: in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and... Agent: Novartis Institutes For Biomedical Research, Inc.

20100130507 - Prostaglandin derivatives: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.... Agent: Arent Fox LLP

20100130508 - Pharmaceutical composition comprising 2,3-dihydro-6-nitroimidazo [2,1-b] oxazole derivatives: A pharmaceutical composition according to the present invention comprises: (I) at least one member selected from the group consisting of oxazole compounds, optically active isomers thereof, and salts thereof, the oxazole compounds being represented by general formula (1): wherein R1 represents a hydrogen atom or C1-6 alkyl group; n represents... Agent: Sughrue Mion, PLLC

20100130509 - Novel antibiotics: The invention relates to the field of antibiotic compositions, both inside and outside the medical field. Presented is a new class of antibiotic compounds, variants of bis(1-aryl-5-tetrazolyl)methanes, which are especially useful for combating infections with gram-positive bacteria and especially MRSA.... Agent: Lucas & Mercanti, LLP

20100130510 - Compounds for inflammation and immune-related uses: The invention relates to certain compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.... Agent: Synta Pharmaceuticals Corp. C/o Wolf, Greenfield & Sacks, P.C.

20100130511 - Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.... Agent: Metabolex, Inc. C/o Swiss Tanner, P.C.

20100130513 - Benzimidazoles and analogs thereof as antivirals: wherein RN1 is a substituent of formula G1-NX1X2, wherein G1 is an optionally further substituted alkylene, which optionally forms, together with RN2, a cyclic group, and each of X1 and X2 is independently H or an N-substituent, or X1 and X2 together form a heterocyclic ring, or X1 together with... Agent: Isis Pharmaceuticals Inc

20100130512 - Fused-ring heterocycle opioids: e

20100130514 - Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes: The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. That is, the present invention provides fused heterocyclic derivatives represented by the following general formula (I), pharmaceutical compositions containing the same, medicinal uses thereof and the like. In the... Agent: Sughrue Mion, PLLC

20100130515 - Polymorphs and solvates of a pharmaceutical and method of making: Polymorphic and solvated forms of solid 3-(4-amino-3-methylbenzyl)-7-(furan-2-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine, and methods of making them, are described.... Agent: Steptoe & Johnson LLP

20100130516 - Purinyl derivatives and their use as potassium channel modulators: This invention relates to novel purinyl derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.... Agent: Birch Stewart Kolasch & Birch

20100130517 - New 4,8-diphenyl-polyazanaphthalene derivatives: New inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) are disclosed herein, as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100130518 - Mapk/erk kinase inhibitors: Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.... Agent: Takeda San Diego, Inc.

20100130519 - Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP

20100130520 - Combination therapy: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP

20100130521 - Method of treatment using fused aromatic compounds having anti-diabetic activity: Fused aromatic compounds of Formula I are PPAR gamma agonists or partial agonists and are useful for weekly dosing in the treatment or control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.... Agent: Merck

20100130522 - Compounds for inflammation and immune-related uses: s

20100130523 - Mono-hydrochloric salts of an inhibitor of histone deacetylase: This invention provides novel crystalline forms of mono-HCl salts and a mono-HCl salt hydrate of JNJ-26481585, an inhibitor of histone deacetylases. The invention also relates to processes for production of these forms, to intermediates used in these processes, to pharmaceutical compositions comprising these forms, and to the use of these... Agent: Philip S. Johnson Johnson & Johnson

20100130524 - Therapeutic or prophylactic agent for dyskinesia: i

20100130525 - Aqueous solution preparation containing camptothecin compounds:

20100130527 - Individualized cancer treatment: Methods to formulate treatments for individual cancer patients by assessing genomic and/or phenotypic differences between cancer and normal tissues and integrating the results to identify dysfunctional pathways are described.... Agent: Morrison & Foerster LLP

20100130526 - Methods for disease therapy: The present invention discloses disease-linked SNPs, microRNAs, and microRNA-targeted mRNAs relevant to the pathogenesis of several major human disorders including, but not limited to, multiple types of cancers, type 2 diabetes, type 1 diabetes, Crohn's disease, coronary artery disease, hypertension, rheumatoid arthritis, bipolar disorder. Also provided are methods for the... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100130528 - Adamantane modulators of nmda receptor and/or 5ht3 receptor: The present invention relates to new adamantane modulators of NMDA receptors and/or 5HT3 receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100130529 - Method of stabilizing imiquimod: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100130536 - Methods for controlling formation of imiquimod impurities for two months, four months, and six months: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100130534 - Methods for reducing imiquimod impurities for two months, four months, and six months: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100130535 - Methods for stabilizing imiquimod for two months, four months, and six months: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100130531 - Pharmaceutical creams with reduced imiquimod impurities: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100130533 - Pharmaceutical creams with refined oleic acid: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100130532 - Reduction of imiquimod impurities in pharmaceutical creams: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100130530 - Reduction of imiquimod impurities using refined oleic acid: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100130537 - Cinnamide compounds for dementia: The invention provides methods for treating, preventing, and delaying the onset of dementia and mild cognitive impairments by administering to a patient in need thereof at least one cinnamide compound and one or more second-line active ingredients, such as cholinesterase inhibitors; AMPA receptor antagonists; NMDA receptor antagonists; and the like.... Agent: Birch Stewart Kolasch & Birch

20100130540 - Azaquinolinone derivatives and uses thereof: The present invention provides compounds and methods for treating or preventing the development of a disease, disorder, or condition in a subject or patient.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100130538 - Bicyclic compound and pharmaceutical use thereof: wherein R1 is a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or a heterocyclic group optionally having substituent(s); R2 is a hydrogen atom or a hydrocarbon group optionally having substituent(s); Xa and Xb are each C, N, O or S; Xc and Xd... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100130539 - Imidazopyridine inhibitors of iap: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein Q, X1, X2, Y, Z R1, R2, R3, R3′, R4, R4′, R5, R6, R6′ and n are as described herein.... Agent: Genentech, Inc.

20100130541 - Processes for the preparation of clopidogrel: The invention relates to processes for the preparation of clopidogrel and salts thereof. The inventors have developed a process for preparing racemic clopidogrel by racemizing R(−) clopidogrel. The process includes the step of reacting R(−) clopidogrel with a powered anhydrous base in one or more solvents.... Agent: Bio Intellectual Property Services (bio Ips) LLC

20100130542 - Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same: The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and sodium bicarbonate. Methods of using such compositions are also provided... Agent: Mayer Brown LLP

20100130543 - Pyrazole carboxamide inhibitors of factor xa: The present invention relates to new pyrazole carboxamide inhibitors of factor Xa, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group, LLC

20100130544 - Use of parasympatholytic substances to enhance and accelerate stem cell differentiation, related methods and compositions: The invention refers to the in vitro and in vivo use of parasympatholytic substances, preferably scopolamine, to potentiate and accelerate the differentiation of stem cells into cells with a tissue-specific phenotype, and the process and compositions related thereto.... Agent: Steinfl & Bruno

20100130545 - Bridged six-membered ring compounds: The invention relates to compounds of formula (I), wherein R1, R2, R1a, R2a, R3, R4, A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.... Agent: Hoxie & Associates LLC

20100130548 - Biphenyl derivatives as modulators of voltage gated ion channels: Biphenyl derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions.... Agent: Vertex Pharmaceuticals Inc.

20100130546 - Quinolone compound and pharmaceutical composition: or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and... Agent: Sughrue Mion, PLLC

20100130547 - Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide: The present invention relates to solid state forms, for example, crystalline forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, pharmaceutical compositions thereof, and methods therewith.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100130549 - Psychotropic compounds, compositions and methods of use: The present invention provides a method for treating or preventing a disease or disorder treatable by the inhibition of serotonin reuptake in a patient, and/or norepinephrine reuptake and/or dopamine reuptake in a patient, the method comprising administering to the patient a neurotransmitter reuptake inhibiting-effective amount of at least one compound... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100130550 - Ocular formulations of norketotifen: Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen.... Agent: Nields, Lemack & Frame, LLC

20100130551 - Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same: Compositions and methods effective to minimize or eliminate the presence of oxidative degradation products in solid dosage forms comprising sufentanil are provided.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP/acelrx

20100130552 - Therapeutic agents useful for treating pain: A compound of Formula: (I) or a pharmaceutically acceptable derivative thereof, where Ar1, Ar2, X, R3, and m are as disclosed herein. Compounds of Formulae (I)-(V) and pharmaceutically acceptable derivatives thereof; compositions comprising an effective amount of a compound of Formulae (I)-(V) or a pharmaceutically acceptable derivative thereof; and methods... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100130555 - Compositions and methods for treating or preventing hypoxic or ischemic injury: c

20100130553 - Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxido-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in the treatment of cranial traumas: The invention relates to the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the preparation of a medicament for use in the treatment of cerebral traumas.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100130554 - Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease: The present invention relates to the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in the form of a hydrate, of a solvate, of a base or of an addition salt with an acid, for preparing a medicament for use in the treatment of motor disorders related to Parkinson's disease.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100130556 - Ep2 receptor agonists: A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20alkyl group; L′ is a single bond, —O— or —C(═O)—; A is selected from the group consisting of: formulae (i) (ii) (iii) wherein X and Y are... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz And Cohn

20100130558 - Novel substituted octahydrocyclopenta[c]pyrrol-4-amines as calcium channel blockers: c

20100130557 - Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions: The present invention relates to substituted arylsulphonylglycines of general formula (I) wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof, which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100130559 - Novel phenyl-isoxazol-3-ol derivative: The present invention relates to a compound represented by formula (I), which has a GPR120 agonist action and thus is useful for treatment of diabetes mellitus or hyperlipidemia, or a pharmaceutically acceptable salt thereof. In the formula, (AA) represents a phenyl or the like, which may be substituted with a... Agent: Merck

20100130561 - Controlling pests by combining insecticides and transgenic plants by applying directly to leaves and roots: The invention relates to a method for controlling pests using a combination of insecticides and transgenic plants and consequently improving the utilization of the production potential of transgenic plants which comprises treating the plant with active compound combinations comprising an active compound from the group of the anthranilamides and at... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100130560 - Fungicide 2-pyridyl-methylene-thio carboxamide or 2-pyridyl-methylene-n-substituted carboximidamide derivatives: The present invention relates 2-pyridyl-methylene-thiocarboxamide or 2-pyridyl-methylene-N-substituted-carboximidamide derivatives of formula (I) wherein A represents a carbo-linked 5-membered heterocyclyl group; T represents S, N—Ra, N—ORa, N—NRaRb or N—CN; Z1 represents a substituted or non substituted C3-C7 cycloalkyl; Y represents a C1-C5-halogenoalkyl comprising up to 9 halogen atoms that can be the... Agent: Ostrolenk Faber Gerb & Soffen

20100130563 - Inhibitors of plasma kallikrein: The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.... Agent: Townsend And Townsend And Crew, LLP

20100130562 - Stabilized nicotine chewing gum: A nicotine chewing gum composition with improved stability.... Agent: Hedman & Costigan P.C.

20100130564 - Small molecule inhibitors of bcl6: Provided are methods of inhibiting BCL6 repression in a mammalian cell. Also provided are methods of treating cancer in a mammal.... Agent: Amster, Rothstein & Ebenstein LLP

20100130565 - Thioamide compounds, method of making and method of using thereof: o

20100130566 - Treatment of autism spectrum disorders with agents that activate the locus coeruleus - noradrenergic system: Methods are provided for treating autism spectrum disorders (ASD) using agents that activate the locus coeruleus-noradrenergic (LC-NA) system of the brain and for screening for compounds for treating ASD comprising determining whether or not the compounds activate the LC-NA system.... Agent: Amster, Rothstein & Ebenstein LLP

20100130567 - Medical agent for prevention or treatment of alzheimer 's disease: A method of treating or preventing Alzheimer's disease or mild cognitive impairment which is an early state of cognitive impairment including Alzheimers' disease by administering a pharmacologically effective amount of an angiotensin II receptor blocker. A method of improving cerebral circulation or cerebral blood flow disorder by administering a pharmacologically... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100130568 - Topical compositions comprising telmesteine for treating dermatological disorders: This invention relates to topical compositions, such as creams and lotions, that comprise or consist essentially of Telmesteine, or a pharmaceutically acceptable salt thereof, as the active ingredient, and methods for their use in treating a variety of dermatological diseases and disorders, including atopic, dermatitis (eczema), allergic contact dermatitis, seborrheic... Agent: Marshall, Gerstein & Borun LLP

20100130570 - Fungicide n-5-membered fused heteroaryl-methylene-n-cycloalkyl-carboxamide derivatives: The present invention relates N-5-membered, fused, heteroaryl-methylene-N-cycloalkyl-carboxamide derivatives, their thiocarboxamide or N-substituted carboximidamide analogues, all of formula (I) wherein A represents a carbo-linked 5-membered heterocyclyl group; T represents O, S, N—Rc, N—ORd, N—NRcRd or N—CN; Z1 to Z3; W1 to W5; Y1 to Y3 and p represent various substituents; their... Agent: Ostrolenk Faber Gerb & Soffen

20100130569 - Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient: The invention provides a novel prophylactic or therapeutic agent for a posterior ocular disease. Pramipexole which is a non-ergot selective D2 receptor agonist or a salt thereof exhibits excellent inhibitory effect on neovascularization, suppressive effect on photoreceptor cell damage and suppressive effect on vascular hyperpermeability in a posterior ocular tissue... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100130571 - Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise... Agent: Seed Intellectual Property Law Group PLLC

20100130572 - Cytoskeletal active compounds, composition and use: The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases... Agent: Howery LLP

20100130573 - Treatment and prevention of deleterious effects associated with alcohol consumption: The present invention provides to methods and compositions that treat or prevent deleterious effects associated with alcohol consumption including alcohol-induced flush reaction and hangover. The methods and compositions include famotidine and optionally succinic acid. The present invention further demonstrates compositions that include famotidine are effective at treating symptoms associated with... Agent: Biotech Beach Law Group , PC

20100130575 - Compound with anesthetics activity, methods for its production and pharmaceutical compositions comprising the same: The present invention is related to a new series of chemical compounds, namely 3-benzyl-imidazolidine-2,4-dione substituted in the position 2 and/or 6 of benzyl ring by halogens as presented to the molecule named LPSF-PT-31, GIRSUPAN and its therapeutic use as drug with analgesic, sedative and adjuvant of anesthetics activities. The invention... Agent: Fildes & Outland, P.C.

20100130574 - Neurodegenerative diseases and methods of modeling: This invention relates to methods for neuroprotection, promoting survival of motor neurons and the treatment of motor neuron diseases by preventing cell signaling through the classic prostaglandin D2 receptor DP1.... Agent: David S. Resnick

20100130576 - Pharmaceutical composition: i

20100130577 - Pyrazalone derivative formulations: Pyrazolone derivative formulations are provided. The formulations include a pyrazolone derivative active agent, e.g., edaravone, and an amphiphilic solubilizing agent. Also provided are methods of making and using the subject formulations.... Agent: Bozicevic, Field & Francis LLP

20100130578 - Active ingredient combinations having insecticide and acaricide properties: The new active compound combinations comprising compounds of the formula (I) and the active compounds (1) to (3) recited in the description possess very good insecticidal and/or acaricidal properties.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100130579 - Cancer therapy: The present invention relates to methods of inducing expression of an epigenetically silenced gene, RASSF1A, in cells, particularly human cells, such as cancer cells. It also relates to methods of treating an individual, prophylactically or therapeutically, for cancer in which RASSF1A is epigenetically silenced.... Agent: Wolf Greenfield & Sacks, P.C.

20100130580 - Formulations and methods for treating dry eye: The present invention provides compositions comprising a low dose amount of an ophthalmic NSAID for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye and... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100130581 - Compounds and methods for the treatment of pain: This invention relates to derivatives of an endomorphin, or of an endomorphin analog, comprising at least one moiety selected from a lipid moiety, a cyclitol moiety and a saccharide moiety.... Agent: Foley And Lardner LLP Suite 500

20100130582 - Indolinone modulators of dopamine receptor: The present invention relates to new indolinone modulators of dopamine receptor, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100130583 - Prolinamide derivatives as modulators of voltage-gated sodium channels: e

20100130584 - Novel compounds from antrodia camphorata: Compounds isolated from the fruiting body of A. camphorata in a solid culture or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds or pharmaceutically acceptable salts thereof.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100130598 - Methods for inducing programmed cell death: The present invention relates to methods for inducing or promoting caspase-independent apoptosis in a cell, the method comprising exposing to the cell an effective amount of a compound of formula I as described herein. The invention also relates to methods for treating or preventing diseases and disorders by administering to... Agent: Merchant & Gould PC

20100130599 - Cyp2c9*8 alleles correlate with decreased warfarin metabolism and increased warfarin sensitivity: The present disclosure is related to a method of identifying a subject with increased sensitivity to warfarin. The method includes identifying a CYP2C9*8 polymorphism in the subject, wherein the presence of said polymorphism is indicative of a patient with increased sensitivity to warfarin relative to a subject having the corresponding... Agent: Morgan, Lewis & Bockius, LLP (sf)

20100130600 - Lipoprotein lipase and its effect on statin treatments: The invention provides methods of treating and prognosing atherosclerosis and lipid response to statin treatment by determining the presence or absence of haplotypes at the lipoprotein lipase locus. In one embodiment, the invention is practiced by evaluating the prognosis of vascular grafts in an individual undergoing statin treatment by determining... Agent: Davis Wright Tremaine LLP/los Angeles

20100130601 - Insecticidal compounds: A compound of formula (I), wherein A1, A2, A3, A4, R1, R2, R3, G1, G2, G3 and Q are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100130602 - Pesticidal composition and method for controlling harmful insects: A pesticidal composition containing: 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate, a saturated hydrocarbon having an initial boiling point of 150° C. or higher and a 95%-distillation temperature of 300° C. or lower, and at least one alkyl carboxylate ester selected from the group consisting of the following esters (i) to (iii): (i) alkyl alkylcarboxylate... Agent: Birch Stewart Kolasch & Birch

20100130603 - Medicament for prophylactic and therapeutic treatment of dermatosis resulting from excessively advanced keratinization: A medicament for prophylactic and/or therapeutic treatment of a dermatosis resulting from excessively advanced keratinization, such as non-hereditary inflammatory keratosis and hereditary congenital keratosis, which comprises a substance selected from the group consisting of a cannabinoid agonist and a vanilloid agonist as an active ingredient.... Agent: Greenblum & Bernstein, P.L.C

20100130604 - Use of rosmarinic acid in manufacture of medicaments for treating or preventing hepatic and renal diseases: The present invention demonstrates through many experiments that Rosmarinic acid (RA) can inhibit the expression of connective tissue growth factor (CTGF) and therefore is useful for the prevention or treatment of hepatofibrosis and nephrofibrosis. Based on this, the present invention provides novel uses of RA and pharmaceutical compositions comprising the... Agent: Turocy & Watson, LLP

20100130605 - Use of derivatives of sinapinic acid and compositions comprising such derivatives: The present invention relates to substances which can be used as cosmetic ingredients, especially for skin whitening and as cosmetic agents against signs of ageing skin. The present invention also relates to the use of such substances for the manufacture of a medicament for the treatment of disorders related to... Agent: Fox Rothschild LLP

20100130606 - Pharmaceutical compositions comprising fesoterodine: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group... Agent: Kenyon & Kenyon LLP

20100130607 - Neuroprotection in demyelinating diseases: Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.... Agent: Biogen Idec / Finnegan Henderson, LLP

20100130608 - Compositions and methods for reducing triglyceride levels: The present invention is directed to methods of reducing plasma triglyceride level in subjects by administering docosahexaenoic acid (DHA). The method can comprise administering daily to the subject a dosage form comprising docosahexaenoic acid ester substantially free of eicosapentaenoic acid (EPA), wherein the DHA is derived from an algal source.... Agent: Dechert LLP

20100130609 - Ester of hexyldecanol having short-chained fatty acids: The present invention relates to the use of one or more esters of 2-hexyldeconal having fatty acids of the general formula (I) R1-COOH, wherein R1 is a linear or branched, saturated or unsaturated alkyl radical having 1 to 6 carbon atoms, in and/or for the production of cosmetic and/or pharmaceutical... Agent: Fox Rothschild LLP

20100130610 - Deodorization and stabilization of marine oils: The invention relates to a process for the preparation of deodorized and stabilized food-grade marine oils by submitting marine oils to a counter-current steam distillation (CCSD) in a thin film column containing a structured packing and, if desired, adding antioxidant(s), to the food-grade marine oils thus obtained and to their... Agent: Nixon & Vanderhye, PC

20100130611 - Omega 3 fatty acid formulations: The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20100130612 - Composition containing chitosan for sustained drug release: The present invention relates to a composition for sustained drug release, comprising chitosan dissolved in a solvent having a pH of below about 4.0, wherein the chitosan is selected from the group of chitosans precipitating in a pH range of between about 3.0 and about 7.5; and at least one... Agent: Schmeiser, Olsen & Watts

20100130613 - Administration of adapalene for modulating the expression of cd1d or il-10: Adapalene or pharmaceutically acceptable salt thereof is administered to an individual in need of such treatment for modulating the expression of CD1d or IL-10 in an inflammatory acneic lesion.... Agent: Buchanan, Ingersoll & Rooney PC

20100130614 - Administration of adapalene for modulating the expression of il-1ra: Adapalene or pharmaceutically acceptable salt thereof is administered to an individual in need of such treatment for modulating the expression of IL-1ra by the cells of acneic epidermis.... Agent: Buchanan, Ingersoll & Rooney PC

20100130615 - Sulfonylurea inhibitors of atp-sensitive potassium channels: The present invention relates to new sulfonylurea inhibitors of ATP-sensitive potassium channels, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100130616 - Salt of aliskiren with orotic acid: The invention relates to a new salt of aliskiren, the respective production and usage, and pharmaceutical preparations containing such a salt.... Agent: Novartis Corporate Intellectual Property

20100130617 - Ethanolamine modulators of nmda receptor and muscarinic acetylcholine receptor: The present invention relates to new ethanolamine modulators of NMDA receptors and/or muscarinic acetylcholine receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100130618 - Treatment of human disease conditions and disorders using vitamin k analogues and derivatives: The present invention is related to the therapeutic uses of vitamin K, its analogues and derivatives in a diverse array of disease conditions. Vitamin K improves blood perfusion and ameliorates hypoxia in prevention and treatment of conditions such as chronic venous insufficiency manifestations, post thrombotic syndrome, skin conditions related to... Agent: Kausakya Santhanam

20100130619 - Pharmaceutical composition for parenteral administration of idebenone: The invention describes use of an injectable form of Idebenone, suitable for intravenous injection or infusion. The proposed formulation is an oil-in-water emulsion, where Idebenone is associated with the oil droplets.... Agent: Alpharx Inc.

20100130620 - Novel use of hydroxytyrosol and olive extracts/concentrates containing it: The present invention is directed to the use of (a composition comprising) hydroxytyrosol for treating or preventing age-related macular degeneration in humans, for maintaining the eye health in animals (preferably in humans), especially in elderly animals (preferably elderly humans), for improving the vision of animals (preferably of humans), for maintaining... Agent: Nixon & Vanderhye, PC

20100130621 - Use of hydroxytyrosol as anti-aging agent: The present invention is directed to the use of (a composition comprising) hydroxytyrosol as anti-aging agent. The composition, to which the present invention is also directed, does essentially not comprise resveratrol and is administered orally to animals. The present invention is further directed to anti-aging methods. “Anti-aging” meaning in the... Agent: Nixon & Vanderhye, PC

20100130622 - Pharmaceutical preparation for preventing and/or treating periodontal disease, agent for oral hygiene comprising thereof, and food comprising thereof: (In the formula, R1 and R2 are independently functional groups selected from a group consisting of a substituted or non-substituted group of a linear alkyl group, a branched alkyl group, a linear alkenyl group and a branched alkenyl group with having the carbon number of 3 to 5. R′1 and... Agent: Kratz, Quintos & Hanson, LLP

20100130623 - Production of stilbenes in plant hairy root cultures and other root cultures: Improved methods for production of stilbenoids including resveratrol, pinosylvin and their respective derivatives are provided, including producing root cultures from plant cells and eliciting production of the stilbenes. The plant cells in an embodiment are contacted with substances which elicit production of the stilbenoid compounds.... Agent: Patricia A. Sweeney

20100130624 - 4-alkyl substituted pyridines as odiferous substances: p

  
05/20/2010 > patent applications in patent subcategories. archived by USPTO category

20100125048 - Cosmetic compositions for skin-tightening and method of skin-tightening using the same: The present invention relates to a skin-tightening cosmetic composition and a method of applying the same, and more specifically, to a cosmetic composition a method of applying the same that includes a hydrolyzed plant protein and glycoprotein. The cosmetic composition includes a hydrolyzed plant protein and glycoprotein in an optimal... Agent: LexyoumeIPGroup, LLC

20100125049 - Polymer factor viii moiety conjugates: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.... Agent: King & Spalding LLP

20100125051 - Parenteral formulations comprising sugar-based esters and ethers: The present invention relates to formulations for the parenteral administration of therapeutic agents, which contain sugar-based esters and ethers of fatty acids and fatty alcohols as surfactants. The formulations are advantageous for therapeutic agents which are insoluble or poorly soluble in water, and for reducing toxicity associated with common surfactants... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100125050 - Process for the manufacture of eptifibatide: Process for manufacturing eptifibatide which comprises subjecting a solution of eptifibatide derivative in a solvent to a concentration step, wherein the pH of said solution is less than or equal to 7.... Agent: Solvay C/o B. Ortego - Iam-nafta

20100125053 - Allosteric modulation of the dopamine transporter protein for the treatment of hiv-1 induced neurologic dysfunction: A method for increasing dopaminergic neurotransmission in a mammal in need of such treatment is provided. The method comprises disrupting Tat-DAT binding in the mammal.... Agent: Dority & Manning, P.A.

20100125054 - Amylin and amylin agonists for treating psychiatric diseases and disorders: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20100125052 - Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents: The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping... Agent: Swiss Tanner, P.C. P.o. Box 1749

20100125055 - Muc-1 cytoplasmic domain peptides as inhibitors of cancer: The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.... Agent: Fulbright & Jaworski L.L.P.

20100125056 - Crystalline form of linaclotide: The present invention relates to crystalline forms of linaclotide, as well as to various methods and processes for the preparation and use of the crystalline forms.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100125100 - Gold nanorod-sirna complexes and methods of using same: Provided are methods and compositions for inhibiting expression of one or more target genes. The compositions contain RNA polynucleotides that can inhibit expression of a target gene via RNA interference (RNAi) electrostatically complexed with surface functionalized gold nanorods (GNRs). The RNA polynucleotides are not covalently bound to the surface functionalized... Agent: Hodgson Russ LLP The Guaranty Building

20100125099 - Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly or abnormally expressed gene: The present invention provides means and methods for alleviating genetic disease. A genetic defect that has a phenotype in differentiated cells can lead to defects in precursor cells thereof. These so-called secondary defects contribute to the overall disease of the individual. In the present invention, genetic intervention with the aim... Agent: Hoffmann & Baron, LLP

20100125101 - Immunostimulatory nucleic acid molecules: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20100125057 - Topical skin care composition: A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.... Agent: Darby & Darby P.C.

20100125058 - Naphthylacetic acids: and pharmaceutically acceptable salts and esters thereof, wherein W, X, Y, and R1-R7 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100125059 - 1-biarylazetidinone derivative: d

20100125060 - Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol: The present invention relates to veterinary or pharmaceutical formulations which may comprise ceftiofur, ketoprofen, benzyl alcohol, or effective combinations thereof. The formulations of the present invention may include a wetting or dispersing agent, a preservative, a flocculating agent or resuspendability enhancer, and/or a biocompatible oil vehicle. This invention also provides... Agent: Judy Jarecki-black Ph.d., J.d.

20100125061 - Naphthylacetic acids: and pharmaceutically acceptable salts and esters thereof, wherein R1-R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I and Z as well as pharmaceutical compositions containing such compounds. The compounds of formula I and... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100125062 - Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors: Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.... Agent: Amgen Inc.

20100125063 - Combinations of nicotinic acetylcholine alpha 7 receptor agonists: Combinations which comprise at least one nicotinic acetylcholine alpha 7 receptor agonist and at least one compound selected from the group consisting of (a) conventional antipsychotics (b) atypical antipsychotics (c) cognition, attention and/or memory enhancers (d) and to use of these combinations in the treatment of psychiatric disorders.... Agent: Fanelli Strain & Haag PLLC

20100125064 - 3-imidazolyl-indoles for the treatment of proliferative diseases: R1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the... Agent: Novartis Institutes For Biomedical Research, Inc.

20100125065 - Carboline derivatives useful in the inhibition of angiogenesis: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy... Agent: Jones Day

20100125066 - Alkylcyclohexylethers of dihydrotetraazabenzoazulenes: wherein R1, R2 and R3 are as described herein, their manufacture, and pharmaceutical compositions containing them. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists. The compounds are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100125067 - Sulfonamide inhibitors of carbonic anhydrase ii: The present invention relates to new sulfonamide inhibitors of carbonic anhydrase II, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100125068 - Methods for inhibiting protein kinases: The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim kinases, and tyrosine kinase using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.... Agent: Merck Patent Department (k-6-1, 1990)

20100125069 - Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100125070 - Bupropion metabolites and methods of their synthesis and use: Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. Methods of making optically pure bupropion metabolites are also disclosed.... Agent: Jones Day

20100125071 - Cxc-chemokine receptor ligands: The present invention relates to compounds of formula (I) with the substituents as defined herein, and uses thereof.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100125072 - Spiro-oxindole compounds and their uses as therapeutic agents: wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions,... Agent: SeedIPLaw Group PLLC

20100125073 - Benzofuran and benzothiophene derivatives useful in the treatment of cancers of the central nervous system: The present invention relates to benzofuran and benzothiophene derivatives and compositions containing such compounds for the production of medicaments for the treatment of cancers of the central nervous system as monotherapy or combination with other agents.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100125074 - Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use: wherein A1, A2, B, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes... Agent: Amgen Inc.

20100125075 - Antibacterial agents: Compounds of formula (II) are antibacterial agents wherein Q represents a radical of the formula: —N(OH)CH(═O) or the formula: —C(═O)NH(OH); R1 represents hydrogen, C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms, or, except when Q is a radical of the formula: —N(OH)CH(═O), a hydroxy, C1-C6 alkoxy,... Agent: Banner & Witcoff, Ltd.

20100125076 - Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use: Substituted sulphonamides having the general formula (I) and salts, hydrates and solvates thereof were prepared and described, wherein R1 is CO or SO2 and R2 is NH or O and where R represents linear or cyclic aliphatic chain and n represents number of linking aliphatic chain carbons (n can be... Agent: Woodcock Washburn LLP

20100125077 - Polymorphs of brimonidine pamoate: A brimonidine pamoate polymorph exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a... Agent: Bausch & Lomb Incorporated

20100125078 - Quinazoline derivatives as nk3 receptor antagonists: R1, R2, R3, R4, R5, and n are as defined herein and to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100125079 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, m, n, q, r, W, Z1, Ar1, Z2, Y, R1, R2, and R3 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods... Agent: Theravance, Inc.

20100125080 - Compounds for inflammation and immune-related uses: The invention relates to certain compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.... Agent: Synta Pharmaceuticals Corp. C/o Wolf, Greenfield & Sacks, P.C.

20100125081 - New compounds 574: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage,... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100125082 - New compounds 578: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage,... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100125084 - Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine: One aspect of the present invention relates to the use of sapacitabine, or a metabolite thereof, in the preparation of a medicament for treating a proliferative disorder, wherein the sapacitabine or metabolite thereof is administered in a dosing regimen comprising at least one treatment cycle, wherein said treatment cycle comprises... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100125085 - Pyridoindole modulators of nmda receptor and acetylcholinesterase: The present invention relates to new pyridoindole modulators of NMDA receptors, AMPA receptors, and/or L-type calcium channels, and/or inhibitors of acetylcholinesterase, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100125087 - New compounds 575: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage,... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100125086 - Use of isoqc inhibitors: The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase-like protein (QPCTL), and the use thereof for the treatment and/or prevention of an inflammatory disease or disorder selected from the group consisting of (a) chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis; (b) other... Agent: Sonnenschein Nath & Rosenthal LLP

20100125089 - Enantiomerically enriched aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof: e

20100125090 - Modulators of atp-binding cassette transporters:

20100125091 - Substituted heterocyclic compounds as ion channel modulators:

20100125092 - 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such... Agent: Theravance, Inc.

20100125093 - Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound: The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.... Agent: Theravance, Inc.

20100125094 - Pyrrolidinyl modulators of nicotinic acetylcholine receptors: The present invention relates to new pyrrolidinyl modulating nicotinic acetylcholine receptor compounds, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100125095 - Biocidal composition of 2,6-dimethyl-m-dioxane-4-ol acetate and methods of use: Provided is a biocidal composition comprising 2,6-dimethyl-m-dioxane-4-ol acetate and an isothiazolinone biocidal compound. The composition is useful for controlling microorganisms in aqueous or water containing systems.... Agent: The Dow Chemical Company

20100125096 - Acetam derivatives for pain relief: The present invention provides a method of treatment, prevention and/or delay of progression of neuropathic pain by a specific dosing regime of acetam derivatives.... Agent: Marshall, Gerstein & Borun LLP

20100125097 - Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof: This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds alone or in combination with formamidine compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to the animal in need... Agent: Judy Jarecki-black Ph.d., J.d.

20100125098 - Treatment of cancer with complex organic-inorganic pigment compositions: The present invention includes compositions and methods for treating disorders of the skin or mucosa resulting from cancer therapies comprising: identifying a patient receiving cancer treatment; and administering to said patient an effective dose of a treated organic/inorganic complex material with an organic dye molecule or derivative thereof, in a... Agent: Chalker Flores, LLP

20100125102 - Estrogenic-active compounds and application thereof: The present invention relates to compounds having estrogenic activity selected from the group consisting of Loliolide, (4S,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one, (4R,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one and analogues thereof. The compounds of the present invention are selective estrogen receptor modulator, which can selectively activate ERβ and simultaneously express high estrogenic activity, and also can be applied as medical... Agent: Wpat, PC Intellectual Property Attorneys

20100125103 - Composition for the treatment of diabetes and metabolic syndrome containing obovatol and its synthesized derivatives: e

20100125104 - Alpha-keto peracids and methods for producing and using the same: The present invention provides α-keto peracids and methods for producing and using the same. In particular, α-keto peracids are useful as antimicrobial agents.... Agent: Don D. Cha

20100125105 - Antimicrobial device and materials for fluid treatment: Compositions comprising miscible blends of antimicrobial bisguanide compounds with certain thermoplastic polymers are provided. These antimicrobial polymeric materials may be further processed into particulate or fiber form for use in fluid treatment devices and processes. The antimicrobial bisguanide compound, such as chlorhexidine, is distributed at the molecular level within at... Agent: Sutherland Asbill & Brennan LLP

  
05/13/2010 > patent applications in patent subcategories. archived by USPTO category

20100120661 - Heterocyclic boronic acid compounds: Dipeptidyl peptidase IV (DPP-IV)-inhibiting compounds are provided that have formula I: wherein n is 1 to 3; X is CH2; S; O; CF2 or C(CH2)2; Z is H; halogen; hydroxyl; (C1-6)alkoxy; (C1-12)alkyl; (C3-12)cycloalkyl; phenyl; or heteroaryl; where the phenyl and heteroaryl groups are optionally mono- or independently plurisubstituted with R7;... Agent: Schwegman, Lundberg & Woessner, P.A.

20100120660 - Highly concentrated insulin solutions and compositions: Highly concentrated insulin solutions and pharmaceutical compositions are described as are methods of their preparation and uses thereof.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100120662 - Glucose uptake modulator and method for treating diabetes or diabetic complications: The present invention relates to an glucose uptake modulator, a pharmaceutical composition comprising the glucose uptake modulator, and a method of treating a diabetes or diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effecting amount of a glucose uptake modulator.... Agent: LexyoumeIPGroup, LLC

20100120667 - Composition for preventing and/or treating peptic ulcers: A composition for effectively preventing or treating peptic ulcers not caused by Helicobacter pylori that does not cause any adverse reaction and thus is highly safe is provided. The present invention relates to a composition for preventing and/or treating peptic ulcers not caused by Helicobacter pylori, which comprises as an... Agent: Sughrue Mion, PLLC

20100120663 - Method for inducing thrombopoiesis: A regime or regimen for inducing the differentiation of multilineage myeloid progenitor cells (CFU-GEMM) into megakaryocyte progenitor cells and, optionally, into megakaryocytes, that are able to produce platelets both in vivo and in vitro, includes a step a) of administering a thus effective amount of erythropoietin, derivative or agonist thereof... Agent: Buchanan, Ingersoll & Rooney PC

20100120666 - Methods of treatment using glycopegylated g-csf: The present invention provides a glycopegylated G-CSF that is therapeutically active and which has pharmacokinetic parameters and properties that are improved relative to an identical, or closely analogous, G-CSF peptide that is not glycopegylated. Furthermore, the invention provides methods for mobilizing hematopoiesis in a subject, particularly a subject who has... Agent: Leydig Voit & Mayer, Ltd

20100120664 - Modified coagulation factors with prolonged in vivo half-life: The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100120665 - Treatment of diseases characterized by inflammation: The invention provides, in part, methods, nucleic acids, vectors, proteins and binding molecules that can be used to modulate a pathway such as a complement pathway. These methods and compositions can be utilized, inter alia, for the study and/or treatment of various conditions or diseases related to a complement pathway.... Agent: Wellstat Management Company. LLC

20100120668 - Method of treatment of photodermatoses: A method for prophylactic or therapeutic treatment of photodermatoses that are caused or exacerbated by or associated with UVR exposure in a subject, particularly a human subject, which comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to reduce the photosensitivity of the skin... Agent: Polsinelli Shughart PC

20100120669 - Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase: m

20100120672 - cyclic peptide compounds: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, a process for preparation thereof, a pharmaceutical composition comprising the same, and a method for prophylactic and/or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100120670 - Cyclised alpha-conotoxin peptides: This invention relates to an oral or enteral pharmaceutical preparation comprising at least one synthetically cyclised alpha-conotoxin peptide having an amide cyclised backbone such that the peptide has no free N- or C-terminus, said peptide having the ability to inhibit a nicotinic acetylcholine receptor and comprising four cysteine residues bonded... Agent: Woodcock Washburn LLP

20100120671 - Novel antimicrobial agents: New antimicrobial polymeric agents which are designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device,... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100120677 - Activity of recombinant equine follicle stimulating hormone: The present invention provides methods of producing biologically active recombinant eFSH analogs and methods of increasing reproduction in mammals, particularly equine, using recombinant eFSH analogs. Also provided are methods of producing biologically active single chain recombinant eFSH. The recombinant eFSH analogs of the present invention increase superovulation, follicular development, embryo... Agent: Greenlee Winner And Sullivan P C

20100120681 - Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization: The present invention relates to amino acid sequences that are directed against vascular endothelial growth factor (VEGF), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, compounds and constructs... Agent: Wolf Greenfield & Sacks, P.C.

20100120673 - Bacteriophage lysins for bacillus anthracis: The present disclosure relates to methods, compositions and articles of manufacture useful for the treatment of Bacillus anthracis and S. cereus bacteria and spores, and related conditions. The disclosure further relates to compositions comprising various phage associated lytic enzyme that rapidly and specifically detect and kill Bacillus anthracis and other... Agent: Brinks Hofer Gilson & Lione/ann Arbor

20100120676 - Composition to treat and/or prevent gastrointestinal infection: The invention relates to a composition for the treatment and/or prevention of infection by gastrointestinal pathogens, in particular Helicobacter pylori and/or a disease associated with infection by said gastrointestinal pathogen in mammals.... Agent: Bacon & Thomas, PLLC

20100120686 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have... Agent: Wilson, Sonsini, Goodrich & Rosati

20100120682 - Compositions for increasing body weight, use and methods: Use of an isolated polypeptide comprising an amino acid sequence having a sequence identity of at least 80%, with the amino acid sequence represented by Gly Asn Ser Asp Asp Phe Leu Ser Gln Gln Pro Glu Arg Pro Arg AspVal Lys Leu Ala Arg (SEQ ID NO: 2), or... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100120688 - Erbb interface peptidomimetics and methods of use thereof: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.... Agent: Woodcock Washburn LLP

20100120675 - Inhibitor of the uracil-dna glycosylase enzyme and uses thereof: The present invention relates to a protein which has the capacity to bind to and inhibit the viral uracil DNA glycosylase (UDG) enzyme and its use as a therapeutic agent; in particular, as an antiviral agent.... Agent: Darby & Darby P.C.

20100120674 - Insulin resistance improving agents: The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100120693 - Medicament for improving prognostic survival in therapy of malignant tumor: A medicament for improving prognostic survival in therapy of malignant tumor is provided that may improve prognostic survival in DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. The medicament according to the invention comprises as a main active ingredient Activated Protein C, which... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100120680 - Method of treating hepatitis c virus: A method of treating or inhibiting hepatitic C virus (HCV). The method comprises administering an effective amount of at least one pokeweed antiviral protein (PAP) mutant alone or in combination with other anti-HCV agents.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100120685 - Methods and compositions for the treatment of cancer: Oligopeptides which can be used to treat cancer are disclosed. Further disclosed are methods of treating cancer, including breast cancer, skin cancer, prostate cancer and multiple myeloma (MM). These methods include administration of a polypeptide encoded by the Mesd gene, or an oligopeptide comprising a contiguous subsequence of a Mesd... Agent: Washington University-snr C/o Sonnenschein Nath & Rosenthal L.l.p

20100120687 - Modulating apoptosis: The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-κB activity. The modulators may be used, for example, in the treatment of NF-κB-mediated diseases, conditions, and injuries.... Agent: Polsinelli Shughart PC

20100120684 - Mutants of interleukin- 1 receptor antagonist and uses thereof: The invention provides an isolated polypeptide comprising a variant amino acid sequence of SEQ ID NO: 1, or a fusion or derivative of said polypeptide, or a fusion of a said derivative thereof, wherein the polypeptide, fusion or derivative retains a biological activity of wild type IL-IRa. In one embodiment,... Agent: Morrison & Foerster LLP

20100120691 - Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration: Neuregulin, a known neuroprotein, has been found to ameliorate or prevent damage caused by mechanical or chemical assault to blood vessels and, when administered into the cerebral spinal fluid, can ameliorate damage to neuronal tissue caused by stroke or inflammation. Additionally, neuregulin has been found to be useful for enhancement... Agent: Morris Manning Martin LLP

20100120692 - Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration: Neuregulin, a known neuroprotein, has been found to ameliorate or prevent damage caused by mechanical or chemical assault to blood vessels and, when administered into the cerebral spinal fluid, can ameliorate damage to neuronal tissue caused by stroke or inflammation. Additionally, neuregulin has been found to be useful for enhancement... Agent: Morris Manning Martin LLP

20100120678 - Novel inhibitors of the egfr kinase targeting the asymmetric activating dimer interface: The invention provides methods and compositions for the modulation of EGFR activity, in particular, inhibition of EGFR activation through an allosteric mechanism is discloses, as is a method for targeted drug discovery and design based on models of the three dimensional structure of the kinase domains of the protein dimers.... Agent: Morgan, Lewis & Bockius LLP (sf)

20100120689 - Polymer factor viii moiety conjugates: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.... Agent: King & Spalding LLP

20100120690 - Polypeptides having antimicrobial activity and polynucleotides encoding same: The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.... Agent: Novozymes North America, Inc.

20100120683 - Prame derived peptides and immunogenic compositions comprising these: The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA... Agent: Edwards Angell Palmer & Dodge LLP

20100120679 - Targeting nbs1-atm interaction to sensitize cancer cells to radiotherapy and chemotherapy: Provided herein are compositions and methods for use in sensitizing cancer cells to radiation and chemotherapy.... Agent: Ballard Spahr LLP

20100120694 - Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100120695 - Polypeptides that bind membrane proteins: Polypeptides which bind to the helical transmembrane region of membrane proteins are disclosed, as are methods for the design of polypeptides that bind to the transmembrane region of membrane proteins. Also provided are methods for the use of the disclosed polypeptides in various applications, as well as products made through... Agent: Woodcock Washburn LLP

20100120696 - Peptides having activities of epidermal growth factor and its uses: The present invention relates to peptides comprising the amino acid sequence represented by the following formula 1 and having the activities of epidermal growth factor and their uses: Cys-Met-Tyr-Ile-Glu-Linker-Arg-Gly-Asp (1) The EGF-mimicking peptides of the present invention possess identical functions or activities to natural-occurring human EGF and are able to... Agent: Clark & Elbing LLP

20100120697 - Tumor activated prodrugs: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to... Agent: Winstead PC

20100120698 - Low-fat food: A low-fat food containing an amino acid or a peptide which is able to activate a calcium receptor, examples of which include γ-Glu-X-Gly, γ-Glu-Val-Y, γ-Glu-Ala, γ-Glu-Gly, γ-Glu-Cys, γ-Glu-Met, γ-Glu-Thr, γ-Glu-Val, γ-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ-Glu-Met(O), γ-Glu-γ-Glu-Val, γ-Glu-Val-NH2, γ-Glu-Val-ol, γ-Glu-Ser, γ-Glu-Tau, γ-Glu-Cys(S-Me)(O), γ-Glu-Leu, γ-Glu-Ile, γ-Glu-t-Leu, γ-Glu-Cys(S-Me), etc,... Agent: Cermak Kenealy Vaidya & Nakajima LLP Acs LLC

20100120699 - Method for synthesizing kpv tripeptide diamide derivates: The object of the invention is to provide an improved method for synthesizing a KPV tripeptide diamide derivate having the formula (I) such as defined in the specification. The synthesis method according can be implemented with any of the stereoisomers of each of the Lysine (K), Proline (P) or Valine... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100120700 - Methods and compositions for treating cervical cancer: The invention provides methods and compositions for treating pathogen infections, particularly human papillomavirus infections. Specifically, the invention provides a method of screening that involves determining an effect of a candidate agent on binding of an E6 protein from an oncogenic strain of HPV to a polypeptide containing the amino acid... Agent: Townsend And Townsend And Crew, LLP

20100120701 - Compositions and methods for engineering probiotic yeast: The invention provides compositions and methods for engineering probiotic yeast to display α(1,2) fucosylated glycans on their cell surface, and the use thereof in the prevention or treatment of infection.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100120702 - Solid preparation for dialysis: The present invention provides a glucose decomposition-suppressed solid preparation for dialysis among powdery or granular preparations for dialysis containing acetate-free solid organic acids as pH adjusting agents. The present invention provides the solid preparation for dialysis containing electrolytes, glucose and pH adjusting agents characterized in that solid organic acids containing... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100120703 - Compositions and methods for treating cancer: Pharmaceutical compositions comprising sinigrin and a pharmaceutically acceptable carrier and use thereof for treating liver cancer. A method for treatment of liver cancer in a subject comprising administering to the subject in need thereof and suffering from cancer, a pharmaceutically effective amount of sinigrin, is also provided.... Agent: Knobbe Martens Olson & Bear LLP

20100120704 - Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders: A method of inhibiting the secretion of IL-8 and other pro-inflammatory cytokines from cells secreting elevated levels of these compounds is provided. The method includes contacting the cell with a composition comprising a cardiac glycoside such as oleandrin. The cardiac glycoside can be used to treat cystic fibrosis and other... Agent: Black Lowe & Graham PLLC Jeffrey J. King. Esq.

20100120705 - Compositions and products containing s-equol, and methods for their making: A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100120707 - Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same: A dosage comprising an antibiotic, an estrogen, and a progestagen is provided. The dosage can be oral, or administered in other methods, such as intravaginally with a tampon. The dosage can be used for menstrual suppression, contraception, and/or hormone replacement therapy. A method of treating a patient with the dosage... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20100120706 - Macrolides useful against inflammatory and allergic diseases: Macrolide compounds of formula I: with PDF4 inhibiting activity are described, wherein R1 is a residue —Y—X-Q; Y is S, SO or SO2; X is a bond or a linear group consisting of hydrogen atoms and with up to 9 atoms selected from C, N, O and/or S, of which... Agent: Gibbons P.C.

20100120893 - Compositions and methods for inhibiting expression of transthyretin: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.... Agent: Alnylam/fenwick

20100120894 - Intracellular dna receptor: Provided herein are methods of identifying and using compounds that modulate an AIM2 polypeptide-mediated immune response. Further provided herein are methods of treating disease comprising administering to a patient a compound that decreases expression of an AIM2 polypeptide. Further provided herein are methods of providing gene therapy to a patient... Agent: Fish & Richardson P.C.

20100120892 - Methods and compositions for the inhibition of stat5 in prostate cancer cells: The present invention relates to compositions and methods for the treatment of prostate cancer. In certain embodiments, the invention relates to compositions and methods for the inhibition of prostate cancer cell growth, comprising inhibiting the activity of Stat5 in prostate cancer cells.... Agent: Wolf Greenfield & Sacks, P.C.

20100120895 - Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of cyclic nucleotide type 4 phosphodiesterase (PDE4B) gene expression and/or activity, including PDE4B1, PDE4B2, and PDE4B3 gene expression and/or activity. The present invention is also... Agent: Merck C/o Sirna Therapeutics, Inc.

20100120891 - Use of a galectin-1-targeted rnai-based approach for the treatment of cancer: The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of... Agent: Knobbe Martens Olson & Bear LLP

20100120900 - Methods and sequences to preferentially suppress expression of mutated huntingtin: Disclosed herein are methods and sequences to preferentially suppress the expression of the mutated huntingtin (“htt”) protein over expression of the normal htt protein. Also disclosed are methods comprising screening an individual for the heterozygous presence of one or more single nucleotide polymorphisms within the individual's Huntington's genes; administering nucleic... Agent: Kenneth J. Collier - C/o Kathy Illg Medtronic, Inc.

20100120898 - Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma: Provided herein are methods and compositions for the diagnosis, prognosis and treatment of Hepatocellular carcinoma (HCC). Also provided are methods of identifying anti-HCC agents.... Agent: Macmillan, Sobanski & Todd, LLC - Nih/osu

20100120897 - Novel helper plasmid, defective sindbis viral vectors and methods of use thereof: Disclosed herein are new defective Sindbis viral vectors made from a novel Helper plasmid, with differences in envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are vectors produced using the plasmid, methods for producing the vectors, methods for treating... Agent: Darby & Darby P.C.

20100120896 - Once-a-day rna-polymerase inhibiting and elongation factor g (ef-g) inhibiting antibiotic pharmaceutical product, formulation thereof, and use thereof in treating infection caused by methicillin-resistant staphylococcus aureus: Disclosed are once-a-day antibiotic products for treating Methicillin-Resistant Staphylococcus aureus, or “MRSA,” the products comprising: a combination of at least two different antibiotics, wherein one of the at least two different antibiotics is selected from the group consisting of RNA-Polymerase Inhibiting antibiotics and wherein one of the at least two... Agent: Raymond E. Stauffer C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20100120899 - Tumor repressor genes in the prevention of cancer: The present invention provides methods for the use of tumor repressor molecules as a prognostic screen for cancer, risk assessment, prognosis, treatment and prevention of cancer in a subject. Furthermore, this invention provides a method to identify new genes that are tumor repressors.... Agent: Dla Piper LLP (us)

20100120708 - Combination therapy comprising zd6474 and gemcitabine for anti-cancer therapy: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP

20100120709 - Cytidine derivative-containing antitumor agent for continuous intravenous administration: e

20100120710 - Branched alpha-glucan, alpha-glucosyltransferase which forms the glucan, their preparation and uses:

20100120711 - Ampk potentiator containing chito-oligosaccharide: Disclosed herein is a composition for promoting AMPK activity, which comprises a chito-oligosaccharide as an active ingredient. The present composition affects the enzymes related to AMPK and lipid metabolism, and thus helps recovery from the condition lacking energy by various functions of controlling metabolism. Therefore, the present composition can enhance... Agent: Nixon & Vanderhye, PC

20100120712 - Pharmaceutical composition for meniere's disease: The present invention provides pharmaceutical composition for treating Meniere's disease, comprising saccharides or sugar alcohols as an active ingredient and polysaccharides, wherein the ratio by weight of the saccharides or sugar alcohols to the polysaccharides is about 100:2 to 100:50. The pharmaceutical composition of the present invention may eliminate the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100120713 - Compositions containing beta-carotene: The present invention relates to compositions for the enrichment, fortification and/or coloration of food, beverages, animal feed, cosmetics or pharmaceutical compositions comprising at least one modified starch, β-carotene and optionally at least an adjuvant and/or an excipient, wherein a mixture of the composition with water has a color hue in... Agent: Nixon & Vanderhye, PC

20100120714 - Substituted benzene fungicides: Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100120715 - Beta-lactamase inhibitors: Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof.... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100120716 - Macrocyclic hepatitis c serine protease inhibitors and uses therefor: Macrocyclic inhibitors of Hepatitis C protease are provided, the inhibitors including a boronic acid or ester group, a macrocyclic ring of about 13 to 25 atoms including at least two amide linkages, a proline-analogous group, and a connecting segment joining moieties on either side of the proline-analogous group. Methods of... Agent: Schwegman, Lundberg & Woessner, P.A.

20100120718 - Combination therapy of substituted oxazolidinones: The present invention relates to combinations of A) oxazolidinones of the formula (I) with B) acetylsalicylic acid (aspirin) and C) an ADP receptor antagonist, in particular P2Y12 purinoreceptor blocker, to a process for producing these combinations and to the use thereof as medicaments, in particular for the prophylaxis and/or treatment... Agent: Barbara A. Shimei Director, Patents & Licensing

20100120717 - Kinase inhibitors: Compounds are provided for use with kinases that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture in comprising such compounds; methods and intermediates useful for making the compounds; and methods... Agent: Takeda San Diego, Inc.

20100120719 - Lyophilization formulation: This invention relates to a pharmaceutical kit containing a lyophilized preparation of a pyrimidine compound described in the specification. Also disclosed is a lyophilization process for making this preparation.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100120721 - Substituted piperidinophenyl oxazolidinones: The present invention relates to oxazolidinones of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof. The invention also relates to processes for the preparation of the compound of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof, and to pharmaceutical compositions containing the... Agent: Bio Intellectual Property Services (bio Ips) LLC

20100120720 - Use of hmg-coa reductase and farnesyl-pyrophosphate synthase inhibitors for the preparation of a medicine: The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological... Agent: Arent Fox LLP

20100120722 - Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss: and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, R5, U, V, W, X, Y, Z, and n are defined herein. This invention also relates to compositions comprising these compounds and methods for using them. The compounds and compositions of this invention are useful to... Agent: Edwards Angell Palmer & Dodge LLP

20100120723 - Pharmaceutical composition comprising a hot-melt granulated lubricant: The present invention relates to a lubricant granulate prepared using a hot melt granulation process, or thermal-heat process. The lubricant granulate is useful in facilitating the use of higher concentrations of lubricant than typically possible in pharmaceutical compositions. Also provided are pharmaceutical compositions comprising the lubricant granulate. Such pharmaceutical compositions... Agent: Greenlee Winner And Sullivan P C

20100120724 - Pesticidal compositions: Pesticidal compositions containing a pesticidally acceptable carrier, and a synergistic blend of plant essential oils as a pesticidally active ingredient and optionally a synergist, and methods for using same, are disclosed.... Agent: Nixon & Vanderhye, PC

20100120725 - Substituted phenylsulfonamide inhibitors of beta amyloid production: s

20100120726 - 1-methylnicotinamide derivatives and formulations of treatment of lipoprotein abnormalities: The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100120727 - Eflornithine prodrugs, conjugates and salts, and methods of use thereof: In one aspect, the present invention provides a composition of a covalent conjugate of an eflornithine analog with an anti-inflammatory drug. In another aspect, the present invention provides a composition of an eflornithine prodrug. In another aspect, the present invention provides a composition of an eflornithine or its derivatives aspirin... Agent: Wilson, Sonsini, Goodrich & Rosati

20100120728 - Method of treating vitamin d insufficiency and deficiency: The invention relates to methods and compositions for reducing toxicity associated with administration of vitamin D3, its 25-hydroxylated and 1-hydroxylated forms, and analogs thereof.... Agent: Marshall, Gerstein & Borun LLP

20100120729 - Pheromone-containing cosmetic agents: Cosmetic substances having 1x×10−7 to 1×10−2 percent by weight of at least one steroid chosen from among certain 16-androstene and estrene steroids, and 0.1 to 30.0 percent by weight of at least one film-forming and/or solidifying polymers. Also disclosed is the use of those cosmetic substances for treating keratin fibers,... Agent: Henkel Corporation

20100120731 - 3-([1,2,4]triazolo [4,3-a]pyridin-7-yl)benzamide derivatives: New inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) are disclosed herein, as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100120730 - 6-benzyl-2,3,4,7-tetrahydro-indolo [2,3-c] quinoline compounds useful as pde5 inhibitors: wherein R1 to R8 and R11 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof, and the stereoisomers of the compounds, the salts, the N-oxides of the compounds and the N-oxides of the salts thereof are effective inhibitors of... Agent: Nath & Associates PLLC

20100120732 - Agent for prevention and/or treatment of systemic lupus erythematosus: Provided is an agent for prevention and/or treatment of systemic lupus erythematosus, which comprises, in combination, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazine-3-one or a solvate thereof and a corticosteroid. The pharmaceutical agent of the present invention is orally administrable, has fewer adverse effects, exhibits an excellent effect of suppressing the symptoms associated with SLE, and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100120734 - Formoterol/steroid bronchodilating compositions and methods of use thereof: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided... Agent: Lucas & Mercanti, LLP

20100120733 - Steroid modulators of glucocorticoid receptor: The present invention relates to new steroid modulators of glucocorticoid receptor activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100120735 - Compound showing anti-inflammatory activity and antiviral activity, pharmaceutical compositions comprising the same, a process for obtaining the same and use of the same in the treatment of epidemic keratoconjunctivites and herpetic stromal keratis: can be a single bond or double bond, to the pharmaceutical compositions comprising the same, to a process for preparing the same and to the use of the same for preparing pharmaceutical compositions. Particularly, the compounds of the invention are particularly useful for preparing ophthalmic pharmaceuticals for the treatment of... Agent: The Nath Law Group

20100120736 - Mineralocorticoid receptor antagonists: Compounds of the formula (I) are provided having a steroid skeleton and substitution characteristics in the A and B rings of the steroid skeleton effective for mineralocorticoid receptor antagonism, and rings C and D of the steroid skeleton having substituents thereon according to formula (I), wherein R1 is —OH or... Agent: Organon Usa, Inc. C/o Merck

20100120737 - Amorphous ciclesonide: The present invention relates to amorphous ciclesonide, methods to prepare the same, pharmaceutical compositions comprising amorphous ciclesonide as active ingredient, and methods of treatment using amorphous ciclesonide.... Agent: Nath & Associates PLLC

20100120738 - Anti-apoptotic benzodiazepine receptor ligand inhibitors: The present invention provides low molecular weight porphyrin compositions for inhibiting, preventing or delaying the binding of a ligand of a mitochondrial benzodiazepine receptor. The invention also provides pharmaceutical compositions comprising these porphyrin compositions and their use in the treatment of conditions involving the mitochondrial benzodiazepine receptor or interactions between... Agent: Bozicevic, Field & Francis LLP

20100120740 - Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase: The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.... Agent: Morgan, Lewis & Bockius LLP (sf)

20100120739 - Triazolopyridazine protein kinase modulators: The present disclosure relates to triazolopyridazine protein kinase modulators of Formula (I), methods of using these compounds to treat diseases mediated by kinase activity.... Agent: Eli Lilly & Company

20100120741 - Heterocyclic inhibitors of histamine receptors for the treatment of disease: The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.... Agent: Global Patent Group - Kal

20100120742 - Rexinoid compound having alkoxy group: Disclosed is a compound represented by the general formula shown below, which can bind to a retinoid X receptor (RXR), which is one of nuclear receptors, and exhibit an agonistic or antagonistic action. [Wherein, R1 is selected from the group consisting of an alkyl group, an alkenyl group, an alkynyl... Agent: Sughrue Mion, PLLC

20100120743 - 11beta-hydroxysteroid dehydrogenase type 1 active compounds: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment... Agent: High Point Pharmaceuticals, LLC

20100120744 - Acetamidopropane modulators of nmda receptors: The present invention relates to new acetamidopropane modulators of NMDA receptor, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group,llc.

20100120745 - Anti-angiogenic agents and methods of use: The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing... Agent: Connolly Bove Lodge & Hutz LLP

20100120746 - Use of r-10-hydroxy-10,11-dihydro-carbamazepine in neuropathic pain: e

20100120748 - Benzoazepin-oxy-acetic acid derivatives as ppar-delta agonists used for the increase of hdl-c, lower ldl-c and lower cholesterol: The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia... Agent: Philip S. Johnson Johnson & Johnson

20100120747 - Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity: The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least one cholinesterase inhibitor, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20100120749 - Tetrahydroindole derivatives as nadph oxidase inhibitors: The present invention is related to tetrahydroindole derivatives of Formula (I), pharmaceutical composition thereof, methods of preparation thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).... Agent: Baker & Daniels LLP

20100120750 - Methods for inducing polyploidization of megakaryocytes and for treating blood and bone marrow diseases and disorders: Disclosed are methods for inducing polyploidization of megakaryocyte cells and for promoting differentiation of megakaryocyte cells into platelet-producing cells. The methods may be utilized for treating blood and bone marrow diseases and disorders in a subject in need thereof and for identifying agents for treating blood and bone marrow diseases... Agent: Andrus, Sceales, Starke & Sawall, LLP

20100120752 - Muscarinic agonists to treat impulse control disorders: The invention relates to a novel use of compounds and pharmaceutically acceptable salts thereof, which are muscarinic, for example muscarine-1 (M1) agonists. These compounds are useful for the preparation of medicaments for treatment, amelioration or prevention of impulse control disorders. These include impulse control disorders ‘Not Elsewhere Classified,’ such as... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100120751 - Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulenes: wherein R1, R2, R3, X, Y, Z, m and n are as described herein. The compounds according to the invention act as V1a receptor modulators and are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100120753 - Anti-infective agents: where R1 is cyclobutyl-N(Ra)—, n is 1, 2, 3 or 4, and at least one R5 is RaSO2N(Rj)alkyl-. In a non-limiting example, a compound of the present invention is N-[(3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin-3-yl}-1,1-dioxo-1,4-dihydro-1λ6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide. The present invention also features compositions comprising the compounds of the present invention or pharmaceutically acceptable salts, stereoisomers or tautomers... Agent: Paul D. Yasger Abbott Laboratories

20100120754 - Identification and use of small molecules to modulate transcription factor function and to treat transcription factor associated diseases: The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small... Agent: Edwards Angell Palmer & Dodge LLP

20100120755 - Conjugated psychotropic drugs and uses thereof: Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100120756 - Phenothiazine modulators of h1 receptors: The present invention relates to new phenothiazine modulators of H1 receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group,llc

20100120757 - Pyrazolone derivatives as pde4 inhibitors: e

20100120759 - Azadecalin glucocorticoid receptor modulators: The present invention provides a novel class of azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.... Agent: Townsend And Townsend And Crew, LLP

20100120758 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed... Agent: Seed Intellectual Property Law Group PLLC

20100120760 - Benzofuran-carboxamide derivatives as antiviral agents: A compound of the formula (I): as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing a compound of the formula (I) for use in inhibiting hepatitis C virus polymerase and/or of treating or preventing an illness due to hepatitis C virus,... Agent: Merck

20100120761 - Bicyclic heterocyclic compounds as fgfr inhibitors: The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100120763 - Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases: e

20100120762 - Triazine derivatives as inhibitors of phosphodiesterases:

20100120764 - Di-substituted amides for enhancing glutamatergic synaptic responses: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related... Agent: Coleman Sudol Sapone, P.C.

20100120765 - Pyrazolyl substituted xanthines: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent: Clinical Data, Inc.

20100120767 - Pyrimidothiophene compounds: Compounds of formula (1) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment of inter alia, cancer: wherein R2 is a group of formula —(Ar1)m-(Alk1)P-(Z)r-(Alk2)S-Q wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alk′ and Alk 2 are optionally substituted divalent... Agent: Banner & Witcoff, Ltd.

20100120766 - Substituted pteridines: The invention relates to new pteridines which are suitable for treating respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system and cancers. This invention also relates to pharmaceutical compositions containing these compounds.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100120768 - Methods, kits, and compositions for generating new hair follicles and growing hair: The invention features methods, kits, and compositions for generating new hair follicles and growing hair on a subject.... Agent: Clark & Elbing LLP

20100120769 - Cyclohexyl piperazinyl methanone derivatives: e

20100120770 - Thiazolyl compounds useful as kinase inhibitors:

20100120771 - Aurora kinase inhibitors from an encoded small molecule library: The present invention provides, at least in part, compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, R1, x, y, R2, R3, R4a, R4b, R5, R6 and R7 are described herein, as well as methods for their identification, their preparation, pharmaceutical compositions containing them, and... Agent: Mccarter & English, LLP Boston

20100120773 - Method of treating disorders mediated by the fibroblast growth factor receptor: The disclosure includes a method of treating a warm-blooded animal having a disorder mediated by the fibroblast growth factor receptor (FGFR), in particular 8p11 myelo-proliferative syndrome (EMS), pituitary tumors, retinoblastoma, synovial sarcoma, chronic obstructive pulmonary disease (COPD), seborrheic keratosis, obesity, diabetes and related disorders, autosomal dominant hypophosphatemic Rickets (ADHR), X-chromosome... Agent: Novartis Corporate Intellectual Property

20100120772 - P38 kinase inhibitors: Compounds of formula (I) and (II) are disclosed, as well as methods for their identification, their preparation, pharmaceutical compositions containing them, and their use in treating disease. The compounds inhibit the production of TNF-alpha and interleukins (IL) by the inhibition of p38 kinase. They are useful in the treatment of... Agent: Mccarter & English, LLP Boston

20100120779 - 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands: m

20100120776 - Carbocysteine medical foods: Medical foods containing carbocysteine and designed for buccal absorption; useful for treating conditions that benefit from administration of an antioxidant, immunostimulant, and/or mucoregulator, such as COPD.... Agent: Collen A. Beard, Esq.

20100120775 - Farnesoid x receptor agonists: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100120778 - Quinoxaline-based lxr modulators: e

20100120774 - Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use: wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease... Agent: Amgen Inc.

20100120777 - Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin: T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m2. In general, the 10-propargyl-10-deazaaminopterin is administered in... Agent: Larson & Anderson, LLC Re: Msk

20100120782 - Endoparasiticidal gel composition: A homogenous, clear, veterinary gel composition which has a broad spectrum of efficacy against endoparasites over a prolonged period of time and which allows for higher concentrations of a mixture of parasiticidal agents in a single application. This composition is useful for treating and controlling endoparasiticidal infection and infestation in... Agent: Wyeth LLC Patent Law Group

20100120781 - Novel compounds for treatment of cancer and disorders associated with angiogenesis function: Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian... Agent: Hogan & Hartson L.L.P.

20100120780 - Treatments for premature ejaculation in humans: Provided are methods and compositions for the treatment of a sexual dysfunction such as premature ejaculation. In certain embodiments, a NMDA antagonist (e.g., dextromethorphan) is administered to a subject in combination with tramadol or a tramadol derivative to treat premature ejaculation. In certain embodiments, a capsaicinoid (e.g., capsaicin) and/or a... Agent: Reed Smith LLP

20100120783 - Melanocortin receptor agonists: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.... Agent: Birch Stewart Kolasch & Birch

20100120784 - Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Heteroaromatic compounds of structural formula (I) or a pharmaceutically acceptable salt thereof, wherein W is a substituted heteroaryl, X and Y are each independently a bond, —O—, —S—, —S(O)—, —S(O)2—, —NR6—, —C(O)—, —C(CH3)(OH)— or —C(CH3)═CH—, u (I) is an integer from 1 to 4, and Ar is an optionally substituted... Agent: Merck

20100120785 - 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently C(H)═ or N═, provided that at least one of A and B is —N═, n is 1-3, m is... Agent: Eli Lilly & Company

20100120787 - Modification of amyloid-beta load in non-brain tissue: The present invention relates to methods and compositions for modulating levels of amyloid-β peptide (Aβ) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of Aβ levels via selective modulation (e.g., inhibition) of γ-secretase activity. The invention also relates to methods of preventing, treating... Agent: Casimir Jones, S.c.

20100120786 - Piperazine derivatives: This invention relates to novel compounds that are piperazine derivatives, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel piperazine compounds that are derivatives of the chemokine CCR5 receptor antagonist, vicriviroc. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100120788 - Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells: The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., prostate cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases,... Agent: Louis J. Wille Bristol-myers Squibb Company

20100120789 - Compound: e

20100120791 - Cyclohexyl sulfonamide derivatives:

20100120790 - Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity: The present invention provides a novel heterocyclic compound containing a beta-amino group, a method for preparing the same, and a pharmaceutical composition comprising the same heterocyclic compound or a pharmaceutically acceptable salt thereof as an active ingredient. The heterocyclic compound of the present invention exhibits excellent DPP-IV inhibitory activity and... Agent: Lucas & Mercanti, LLP

20100120794 - Cycloalkylamino acid derivatives: and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof; wherein B, D, E, R1, R2, R3, R4, R5, R8, m, n, p, q, r, s, t and u are as defined herein. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases... Agent: Pfizer Inc

20100120793 - Pyrrolidines: This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutically acceptable derivatives thereof, to their use in medicine, to compositions containing them, and to processes for their preparation. It also relates to intermediates used in the preparation of such compounds and derivatives. In particular the compounds... Agent: Pfizer Inc. Patent Department

20100120792 - Substituted 2,3,4,5-tetrahyrdo-1h-pyrido[4,3-b]indoles, methods for the production and use thereof: R1 represents amino group substituent selected from optionally substituted C1-C5 alkyl; R2, is one or more substituents selected from hydrogen, halogen, C1-C3 alkyl, CF3, OCF3; Ar is phenyl optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, substituted amino group, or CF3; or optionally substituted aromatic 6-membered heterocycle comprising 1-2 nitrogen... Agent: Sughrue Mion, PLLC

20100120795 - Powders for reconstitution: This invention relates to powders for reconstitution comprising the NNRTI TMC278 dispersed in certain water-soluble polymers, which can be used in the treatment of HIV infection.... Agent: Philip S. Johnson Johnson & Johnson

20100120796 - Compositions and methods for treatment and prevention of hyperuricemia related health consequneces: Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods... Agent: Beusse Wolter Sanks Mora & Maire

20100120797 - Purinyl derivatives and their use as potassium channel modulators: This invention relates to novel purinyl derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.... Agent: Birch Stewart Kolasch & Birch

20100120798 - Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety: The invention provides compounds of the formula (I) having PKA and PKB kinase inhibiting compounds of the formula (I): GP 1 J T 2 J N 4 R N H (I) or salts, solvates, tautomers or N-oxides thereof, wherein (1) GP is a group GP1: HET 2a a Q G... Agent: Heslin Rothenberg Farley & Mesiti PC

20100120799 - Purine derivatives as immunomodulators: Het is a 5- or 6-membered saturated aliphatic heterocycle containing one oxygen heteroatom, which heterocycle may be substituted by one or two C1-4alkyl groups, and salts and solvates thereof, are inducers of human interferon and may be useful in the treatment of various disorders in particular infectious diseases, cancer, and... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100120800 - Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof: There is provided an agent for preventing the recurrence of cerebrovascular disorder and an agent for ameliorating troubles following cerebrovascular disorder and inhibiting the progress thereof which contain a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salts thereof.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100120801 - Akt and p70 s6 kinase inhibitors: e

20100120802 - Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (no) production:

20100120804 - Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors:

20100120803 - 3,4-dihydroquinazoline derivatives: The present invention relates to 3,4-dihydroquinazoline derivatives, a process of preparing them and a pharmaceutical composition including them. The 3,4-dihydroquinazoline derivatives of the present invention have excellent T-type calcium channel blocking effect and anti-cancer activity.... Agent: Sughrue Mion, PLLC

20100120805 - Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors: e

20100120806 - Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities: Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases,... Agent: Wilmerhale/deciphera Pharmaceuticals

20100120807 - Compounds and compositions as modulators of gpr119 activity: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.... Agent: Genomics Institute Of The Novartis Research Foundation

20100120809 - Aryl heterocyclic cgrp receptor antagonists: (wherein variables A1, A2, B, m, n, J, X, R4, G1, G2, G3 and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed... Agent: Merck

20100120808 - Spirocyclic heterocyclic derivatives and methods of their use: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.... Agent: Feldman Gale, P.A.

20100120810 - Compounds and methods for modulating rho gtpases: The present invention relates to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac GTPases (Rac1, Rac1b, Rac2 and/or Rac3).... Agent: Nixon & Vanderhye, PC

20100120814 - Crystalline and amorphous forms of naltrexone hydrochloride: The present invention relates to novel crystalline forms of naltrexone hydrochloride including hydrated and solvated forms and a novel amorphous form. The invention also describes methods of preparing the various crystalline forms. The present invention also relates to pharmaceutical compositions containing crystalline and amorphous forms of naltrexone hydrochloride, as well... Agent: Mallinckrodt Inc.

20100120811 - Long-acting injectable analgesic formulations for animals: Long acting injectable analgesic formulations and methods for providing long lasting pain relief in animals are disclosed.... Agent: Judy Jarecki-black, Ph.d., J.d.

20100120812 - Medicinal compositions comprising buprenorphine and naltrexone: An analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount of naltrexone such that the ratio by weight of buprenorphine to naltrexone delivered to or reaching the plasma of a patient is in... Agent: Troutman Sanders LLP 5200 Bank Of America Plaza

20100120813 - Peripheral opioid receptor antagonists and uses thereof:

20100120815 - Stable solid preparation containing 4,5-epoxymorphinan derivative: That is, the present invention provides the stable solid preparation comprising the 4,5-epoxymorphinan derivative or the pharmacologically acceptable acid addition salt thereof as the effective ingredient, and comprising sodium thiosulfate, a sugar or a sugar alcohol and hydroxypropylcellulose having a low degree of substitution in an amount of 1 to... Agent: Birch Stewart Kolasch & Birch

20100120816 - Camptothecin derivatives with antitumor activity: Novel camptothecin derivatives having antitumor activity, the processes for the preparation thereof, the use thereof as antitumor drugs and pharmaceutical compositions containing them.... Agent: Arent Fox LLP

20100120817 - Azonafide derived tumor and cancer targeting compounds: An azonafide-based compound of Formula I, a composition comprising the compound, and a method of using the compound to deliver a cytotoxic azonafide derivative to a cell, as well as related compounds and methods for the use thereof to pre-pare an azonafide-based compound of Formula I.... Agent: Leydig, Voit & Mayer, Ltd.

20100120818 - Substituted tetrahydropyrroloquinolines: Compounds of the formula (I), in which R1, R2, R3, R4, R5, and R6 and m have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100120822 - Method of controlling formation of imiquimod impurities (bha comparator): Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120826 - Method of inducing cytokine biosynthesis: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120828 - Method of inducing interferon biosynthesis: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120824 - Method of preparing a pharmaceutical cream and minimizing imiquimod impurity formation: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120832 - Method of preparing a pharmaceutical cream and minimizing imiquimod impurity formation (at least four months storage): Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120833 - Method of preparing a pharmaceutical cream and minimizing imiquimod impurity formation (at least six months storage): Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120819 - Method of reducing imiquimod impurity formation: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120836 - Method of treating a dermal and/or mucosal associated condition: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120837 - Method of treating a mucosal and/or dermal associated condition: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120820 - Method of treating actinic keratosis: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120823 - Method of treating basal cell carcinoma: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120821 - Method of treating genital or peri-anal warts: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120825 - Method of treating mollescum contagiosum: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120831 - Methods for improving imiquimod availability at two months, four months and six months between refined and compendial: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120830 - Pharmaceutical cream having similar or less levels of imiquimod impurity formation as cream with bha (comparator): Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120835 - Pharmaceutical cream with reduced imiquimod impurities at four months using refined oleic acid: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120834 - Reduction of imiquimod impurities at four months using refined oleic acid: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120829 - X-fold less imiquimod impurities at six months between refined and compendial: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120827 - X-fold less imiquimod impurities at two months between refined and compendial: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20100120838 - Compounds for the treatment of inflammatory disorders: a

20100120839 - Pyrazoles useful in the treatment of inflammation:

20100120841 - Benzimidazole compound and pharmaceutical use thereof:

20100120840 - Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents: Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100120842 - Neurogenesis by muscarinic receptor modulation: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent... Agent: Sughrue Mion, PLLC

20100120845 - Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics: e

20100120843 - Pharmaceutical composition for treating alcohol-induced liver injury comprising (4s,5s)-5-fluoromethyl-5-hydroxy-4-(amino)-dihydrofuran-2-one or pharmaceutically acceptable salt thereof: The present invention relates to a pharmaceutical composition for treating alcohol-induced liver injury comprising (4S,5S)-5-fluoromethyl-5-hydroxy-4-({[(5R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydro-5-isoxazolyl]carbonyl}amino)-dihydrofuran-2-one or pharmaceutically acceptable salt thereof, and a use thereof.... Agent: Birch Stewart Kolasch & Birch

20100120844 - Tetrahydroisoquinoline compound: The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3... Agent: Greenblum & Bernstein, P.L.C

20100120846 - Trpv1 antagonists: e

20100120848 - Stable pharmaceutical formulations of montelukast sodium: The invention encompasses stable pharmaceutical compositions comprising montelukast or salts thereof and methods of preparing the same.... Agent: Kenyon & Kenyon LLP

20100120847 - Styrylquinolines, their process of preparation and their therapeutic uses: The present invention concerns new substituted styrylquinolines, their process of preparation and their therapeutic uses as integrase inhibitors and/or for the treatment and/or prevention of HIV.... Agent: Stites & Harbison PLLC

20100120852 - Aroyl-piperidine derivatives and method of treating disorders induced by substance p: wherein Y is ═N— or ═N(O)—, R is OH when Y is ═N— and R is H when Y is ═N(O)— and the ring A is unsubstituted or mono- or poly-substituted by substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl, provided that when... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20100120849 - Compositions for treating hyperproliferative vascular disorders and cancers: The present invention relates to a pharmaceutical composition for preventing or treating hyperproliferative vascular disorders, and a pharmaceutical anticancer composition comprising the compound represented by the Formula 1. The present compounds exhibit IC50 values of less than 0.16 μM for vascular smooth muscle cells and cancer cells to effectively prevent... Agent: Clark & Elbing LLP

20100120851 - Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma: The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one prenyltransferase inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma comprising a pharmaceutically... Agent: Alcon

20100120850 - Quinoline derivatives, pharmaceutical compositions comprising them, and their use in treating central nervous system and peripheral diseases: Compounds of Formula (I) wherein R1, R2, n and R3 are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100120853 - Derivatives of hypoestoxide and related compounds: Novel diterpene compounds, in particular, hypoestoxide-related compounds, are provided in pure form or as contained in the native plant source, for treatment and prophylaxis of cancer, inflammatory diseases, hyperlipidemias, malaria, and diabetes mellitus. Embodiments also pertain to methods for using the hypoestoxide-related compounds to treat various diseases and symptoms associated... Agent: Pillsbury Winthrop Shaw Pittman LLP

20100120856 - Derivatives of the aminated hydroxyquinoline class for treating cancers: The invention relates to compounds of the animated hydroxyquinoline type capable of preventing the migration of metastases or tumoral cells. Such compounds are useful for treating cancers.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100120855 - Macrocylic inhibitors of hepatitis c virus: Inhibitors of HCV replication of formula (I), the N-oxides, salts, and stereochemically isomeric forms thereof, wherein each dashed line (represented by represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is aryl or a saturated, a partially unsaturated... Agent: Philip S. Johnson Johnson & Johnson

20100120854 - Tgf-beta inhibitors: The present invention provides crystalline 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole monohydrate.... Agent: Eli Lilly & Company

20100120857 - Use of tris-quaternary ammonium salts as pain modulating agents: Provided are tris-quaternary ammonium compounds which are modulators of nociception and pain.... Agent: Crowell & Moring LLP Intellectual Property Group

20100120859 - Novel case of renin inhibitors: The present invention relates to piperidine-based renin inhibitor compounds having carboxylate or carboxylic acid terminal groups, and their use in treating cardiovascular events and renal insufficiency.... Agent: Merck

20100120858 - Piperidine derivatives: e

20100120860 - Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists: The present invention relates to [1-(benzyl)-piperidin-4-yl]-([1,3,4]thiadiazol-2-yl)-amine and [1-(benzyl)-piperidin-4-yl]-(thiazol-2-yl)-amine derivatives of formula (I) that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example... Agent: Philip S. Johnson Johnson & Johnson

20100120861 - Benzoic acid inhibitors of atp-sensitive potassium channels: The present invention relates to new benzoic acid inhibitors of ATP-sensitive potassium channel activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100120862 - Monocyclic compounds and their use as trpv1 ligands: and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount... Agent: Dechert LLP

20100120863 - Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention... Agent: Merck

20100120864 - 2-aminooxazolines as taar1 ligands: or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100120867 - Method of treatment: Improvements in the treatment of patients suffering from frequent heartburn are provided by a treatment regimen comprising administration of an effective daily amount of lansoprazole or a pharmaceutically acceptable salt thereof for up to 14 days.... Agent: Frank A. Smith Novartis Consumer Health, Inc.

20100120865 - Organic compounds: The present invention concerns a compound of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, wherein the groups Ri-Rs are defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100120866 - Process for producing amide compound: There is provided a process for producing an amide compound having an excellent harmful arthropod-controlling activity and represented by the formula (III): wherein R1, R2 and R3 independently represent a C1-C6 alkyl group optionally substituted with at least one halogen atom etc., R4, R5, R6 and R7 independently represent a... Agent: Birch Stewart Kolasch & Birch

20100120868 - Process for preparing solid dosage forms of rosiglitazone maleate: The invention relates to a process for preparing a solid pharmaceutical composition rosiglitazone maleate, comprising the step of adsorption of rosiglitazone maleate onto carrier particles (C) during a dry mixing process.... Agent: Arent Fox LLP

20100120869 - Compounds and methods for pkc theta inhibition: The present invention provides a method of selectively inhibiting PKCθ in the presence of PKCδ, by administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula I. The present invention also provides a method of inhibiting cytokine synthesis in a T cell, a method... Agent: Townsend And Townsend And Crew, LLP

20100120870 - Dispersible pesticidal compositions: Soluble granule pesticidal compositions comprise Flonicamid, a dispersant, and a wetting agent are disclosed.... Agent: Patent Admistrator Fmc Corporation

20100120871 - Hair care compositions, methods, and articles of commerce that can increase the appearance of thicker and fuller hair: Hair care compositions, methods, and articles of commerce that can increase the appearance of thicker and fuller hair. Such compositions can be applied to any areas where a thicker and fuller hair appearance is desired, such as the scalp or face. The present invention also relates to methods of marketing... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100120872 - Organic compounds and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100120873 - Prophylactic or therapeutic agent for age-related macular degeneration: An object of the present invention is to find a novel medicinal use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent inhibitory effect on neovascularization in the choroid and also has a protective effect on retinal pigment epithelial cell damage, and therefore is useful... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100120874 - Heterocyclic gamma secretase modulators:

20100120875 - Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis: A method of treating osteoporosis comprising administering to a subject a composition comprising a compound, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or a salt thereof, is described. A method of inhibiting osteoclast activity and stimulating osteoblast activity in a subject also is described.... Agent: Arent Fox LLP

20100120876 - Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (glp-1) compound or a melanocortin-4 receptor (mc4) agonist peptide: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.... Agent: Kaplan Gilman & Pergament LLP

20100120877 - Additional therapeutic use: The invention relates to the use of an AT1 receptor antagonist or or an AT2 receptor modulator, respectively, or a pharmaceutically acceptable salt thereof, for producing a pharmaceutical preparation for the treatment of conditions or diseases associated with the increase of AT1 receptors in the sub-epithelial area or increase of... Agent: Novartis Corporate Intellectual Property

20100120878 - Formulation: This invention relates to mixtures of triazole compounds and in particular to the use of such mixtures in non-crystallising compositions. It relates to mixtures that are concentrated solutions and also to the use of the concentrated solutions in water diluted form. Furthermore, it relates to the use of such mixtures... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100120879 - Insecticides as safener for fungicides with phytotoxic action: The present invention relates to the use of insecticides which are selected among GABA antagonists and nicotin receptor agonists/antagonists, if appropriate in combination with at least one gibberellin, as safener for fungicides which have a phytotoxic effect. Moreover, the invention relates to a method of reducing or preventing the phytotoxic... Agent: Birch Stewart Kolasch & Birch

20100120880 - Process to prepare new subsituted 1h-benzo[d]imidazol-2(3h)-ones, new intermediates and their use as bace 1 inhibitors: The invention relates to a new process leading to new substituted 1H-benzo[d]imidazol-2(3H)-ones of formula III and III′, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly as BACE 1 inhibitors in the treatment of Alzheimer disease.... Agent: Marsh, Fischmann & Breyfogle LLP

20100120881 - Chemical compounds: The present invention relates to imidazoline derivatives and their use as insecticidal, acaricidal, molluscicidal and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100120882 - Phenoxymethyl imidazoline derivatives and their use as pesticides: The present invention relates to imidazoline derivatives and their use as insecticidal, acaricidal, molluscicidal and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100120883 - Novel compounds: e

20100120884 - Use of dithiine-tetracarboximides for controlling phytopathogenic fungi: The present invention relates to the use of novel and of known dithiine-tetracarboximides for controlling phytopathogenic fungi, and to methods of controlling phytopathogenic fungi in plant protection, and to plant protection compositions comprising these dithiine-tetracarboximides.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100120885 - Novel derivatives of psammaplin a, a method for their synthesis and their uses for the prevention or treatment of cancer: Derivatives of psammaplin A responding to formula (I), a method for their synthesis and their use for the preparation of a medicament for preventing and for treating a tumor or a cancer. Formula (I).... Agent: Morgan Lewis & Bockius LLP

20100120886 - Aryl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders: The present invention relates to aryl-substituted sulfonamides with 5-HT6 receptor affinity, and compositions thereof, and the use of said compounds for the treatment or prophylaxis of various disorders.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100120887 - Sustained release formulation of melatonin: The present invention relates to low-dose formulations of melatonin, and methods of use thereof, which provide a sustained release of melatonin so as to rapidly increase plasma levels of melatonin, maintain a relatively high level (which mimics the endogenous level of a young subject) for approximately 5-6 hours, and then... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100120888 - Atorvastatin strontium salt and pharmaceutical composition comprising same: This invention provides atorvastatin strontium salt or its hydrates or polymorphs having improved water solubility, which is useful for the prevention or treatment of hyperlipidemia and hypercholesterolemia, and a pharmaceutical composition comprising same.... Agent: Sughrue Mion, PLLC

20100120889 - Skin care composition for accelerated production of collagen proteins and method of fabricating the same: A liquid solution for topical application to the skin of an animal consists of solutes and a solvent, where the solutes include ascorbate, tropocollagen factors, copper, and zinc gluconate. The tropocollagen factors include L-proline, glycine and L-lysine.... Agent: Marger Johnson & Mccollom, P.C.

20100120890 - Ion channel modulating activity i: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine... Agent: Seed Intellectual Property Law Group PLLC

20100120901 - Novel compounds, pharmaceutical compositions containing same, and methods of use for same: A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IV wherein R21=H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —CH2OR25, —C(O)R25, —CO(O)R25, —C(O)NR25R26, —CH2C(O)R25, or —CH2C(O)NHR25, where R25 and R26 are each independently H, C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20100120902 - Standarized bioactive herbal extracts: The present invention relates to standardized extracts of Boerhaavia diffusa, wherein the extracts have anti inflammatory and analgesic activities. The present invention also includes bioassay guided fractionation of Boerhaavia diffusa leading to the identification of bioactive markers; processes for the isolation of the bioactive markers; processes for the preparation of... Agent: Ranbaxy Inc.

20100120903 - Anti-inflammatory agent: An anti-inflammatory agent which includes an oil-soluble licorice extract, prepared by subjecting at least one of a leguminous plant of the genus Glycyrrhiza and a water extraction residue of a leguminous plant of the genus Glycyrrhiza to an extraction treatment with an organic solvent and which has at least one... Agent: Arthur G. Schaier Carmody & Torrance LLP

20100120904 - Novel use of genistein: Use of genistein for the treatment and prevention of dry eye syndrome or LKC and corresponding compositions containing it.... Agent: Nixon & Vanderhye, PC

20100120905 - System and method for controlling growth of microorganisms with brominated furanones: A method for inhibiting the growth of a microorganism using an effective amount of one or more of the following synthetic brominated furanones: (i) 4-bromo-5Z-(bromomethylene)-3-methylfuran-2-one; (ii) 3-(dibromomethyl)-5-(dibromomethylene)furan-2-one; (iii) 3-(bromomethyl)-5-(dibromomethylene)furan-2-one; (iv) 4-bromo-3-(bromomethyl)-5Z-(bromomethylene)furan-2-one; or (v) 4-bromo-5-(dibromomethyl)-3-methylfuran-2(5H)-one. The brominated furanones inhibit the growth of both fungi and bacteria, including the fungal species Candida... Agent: Bond Schoeneck & King, PLLC

20100120906 - Modified release formulation and methods of use: A modified release pharmaceutical formulation includes about 30-70% N-(2-amino-4-(fluorobenzylamino)-phenyl)carbamic acid ethyl ester (retigabine), or a pharmaceutically acceptable salt, solvate or hydrate thereof, about 5-30% of a drug delivery matrix including hydroxypropylmethylcellulose (HPMC), about 1.0-10% of an anionic surfactant, and an enteric polymer. The pharmaceutical formulation produces a sustained plasma concentration... Agent: Mcdermott, Will & Emery

20100120907 - Derivatives of amyris alcohols and eudesmol for treating cold sores and herpes: Provided are topical formulations comprising an Amyris alcohol and/or ester derivatives of Amyris alcohol which may be used for the treatment of diseases including herpes virus infection (e.g., HSV-1, HSV-2), epidermoid carcinoma, cold sores, and human papillomavirus. Amyris alcohols contemplated for use with the present invention include valerianol, beta-eudesmol, epi-gamma-eudesmol,... Agent: Reed Smith LLP

20100120908 - Eye drop preparation comprising latanoprost: Disclosed is an eye drop preparation comprising latanoprost, which is characterized in that the degradation of latanoprost in water can be prevented, the adsorption of latanoprost onto a plastic container can be prevented, and therefore the decrease in the latanoprost content can be prevented satisfactorily. The eye drop preparation comprises... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100120909 - Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof: The invention concerns compositions comprising substituted 1,3-diphenylprop-2-en-1-one derivatives designed for therapeutic use. The inventive compositions are useful in particular for preventing or treating cardiovascular diseases, syndrome X, Ia restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative, dermatological diseases and disorders related to oxidative stress,... Agent: Nixon & Vanderhye, PC

20100120910 - Cosmetic compositions comprising esters based on 2-propylheptanol: The invention relates to the use of esters of 2-propylheptanol with benzoic acid and/or benzoic acid derivatives in cosmetic and/or pharmaceutical preparations. The compounds are distinguished by their particularly light sensory impression.... Agent: Fox Rothschild LLP

20100120912 - Esters of capsaicinoids as dietary supplements: Provided are nutraceutical or dietary supplemental compositions comprising esterified capsaicinoids. The esterified capsaicinoids may converted to the active parent capsaicinoid compound following enzymatic or chemical hydrolysis. In various embodiments, these esterified capsaicinoids have a higher lipophilicity, lipid solubility and result in less irritation to the stomach than the parent capsaicinoid,... Agent: Reed Smith LLP

20100120911 - Preservative system for cosmetic formulations: Disclosed is a novel method for preserving cosmetic/personal care formulations through a two component preservative system, said system comprising (a) Component I which functions to eliminate the existing microbial contamination load in a natural cosmetic formulation base through an optimized pasteurization method that avoids deep freezing; and (b) Component II... Agent: Sabinsa Corporation

20100120913 - Resin catalyzed and stabilized peracid compositions and associated methods: Methods, compositions, and system for making and stabilizing peracids in peracid-containing compositions are provided. The method of making can include the contacting of a cationic exchange resin with a carboxylic acid and hydrogen peroxide containing solution and maintaining the peracid in contact with the solution for a period of at... Agent: Thorpe North & Western, LLP.

20100120914 - Medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis: A medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis, which comprises a polyprenyl compound (e.g., 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid) as an active ingredient.... Agent: Greenblum & Bernstein, P.L.C

20100120915 - Antimicrobials and related methods: Compositions for antimicrobial, antibacterial, antiviral, fungicidal and sporicidal applications comprise a mixture of alkyl betaine and alkyl amine oxide components together with a protonating agent. The compositions are particularly effective in the treatment and elimination of microorganisms in planktonic cell form as well as in sessile cell form in biofilms.... Agent: Lynn G. Foster

20100120917 - Butylammonium modulators of fatty acid transport: The present invention relates to new butylammonium modulators of fatty acid transport, and/or removal of toxic acyl-CoA compounds, pharmaceutical compositions thereof, and methods of use thereof... Agent: Global Patent Group - Apx

20100120916 - Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases: wherein R1 and R2 each independently represents a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino... Agent: Sughrue-265550

20100120918 - Novel non-aqueous topical solution of diclofenac and process for preparing the same: A non-aqueous topical solution composition of pharmaceutically acceptable salt of diclofenac is disclosed. The non-aqueous topical solution composition comprises therapeutically effective amount of pharmaceutically acceptable salt of diclofenac, solublizer, penetration enhancer and solvent, and optionally a humectant, counter irritant, additional penetration enhancer and anti-oxidants and a process for preparing the... Agent: Brion Raffoul

20100120919 - Methods for treating transthyretin amyloid diseases: Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed.... Agent: Jones Day

20100120920 - N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress: Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce,... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100120921 - Renin inhibitors for treatment of hypertension in patients with high sodium diet: The present invention relates to methods for the prevention of, delay of progression to, or treatment of hypertension in a patient with a high sodium diet, comprising administering to such a patient a therapeutically effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof.... Agent: Novartis Corporate Intellectual Property

20100120922 - Liquid formulations containing a carotinoid: The present invention relates to a liquid formulation containing at least one carotenoid, at least one hydrophilic protective colloid and at least one water-miscible alcohol. The formulation according to the invention can be added directly to aqueous or non-aqueous preparations. The invention compositions can be used in animal feed, human... Agent: Connolly Bove Lodge & Hutz, LLP

20100120923 - Adhesive complex coacervates and methods of making and using thereof: Described herein is the synthesis of adhesive complex coacervates and their use thereof. The adhesive complex coacervates are composed of a mixture of one or more polycations and one or more polyanions. The polycations and polyanions in the adhesive complex coacervate are crosslinked with one another by covalent bonds upon... Agent: Gardner Groff Greenwald & Villanueva. PC

20100120924 - Novel base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion: The present invention provides a novel base material for a dry solid dispersion, a solid dispersion containing the base material, and a composition containing the dispersion; the solid dispersion of the present invention, which contains a poorly soluble component with improved dissolvability, can be obtained by mixing a polyvinyl alcohol-based... Agent: Edwards Angell Palmer & Dodge LLP

  
05/06/2010 > patent applications in patent subcategories. archived by USPTO category

20100113326 - Dimeric iap inhibitors: Compounds made up of a homodimer or heterodimer having monomeric units of formula (I): wherein: each A is, independently, NR1R2, or N+R1R2R3; each B is, independently, optionally substituted alkyl, alkenyl, or alkynyl, wherein one or more hydrogens are optionally replaced by fluorine; each U is, independently, CONH, C(O)O, C(S)O, C(S)NH,... Agent: Banner & Witcoff, Ltd.

20100113329 - Maleamic acid polymer derivatives and their bioconjugates: The present invention is directed to maleamic acid derivatives of water soluble polymers, to chemically stable water-soluble polymer succinamic acid-active agent conjugates, and to methods for reproducibly preparing, characterizing and using such polymer reagents and their conjugates.... Agent: Nektar Therapeutics

20100113327 - Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein: The present invention relates to methods for selecting a candidate therapeutic agent for controlling mineralization of an extracellular matrix in a tissue of a subject. The invention further relates to a cell culture mineralization model comprising a culture of an extracellular matrix producing cell under conditions that support extracellular matrix... Agent: Morrison & Foerster LLP

20100113328 - Targeted delivery to legumain-expressing cells: The present invention relates to new agents and methods useful for preventing, treating and diagnosing diseases such as cancer. For example, the invention relates to prodrug agents useful for targeting and delivering cytotoxic drugs to cancerous cells.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100113331 - Substituted imidazole derivatives, compositions, and methods of use as ptpase inhibitors: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control,... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20100113330 - Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof: The present invention relates to methods of using Tetrahydropyrido[4,3-d]Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.... Agent: Merck Patent Department (k-6-1, 1990)

20100113335 - Compositions and methods for treatement of cancer: The present invention discloses lentogenic viral strains useful in the treatment of cancer. A preferred viral strain of Newcastle disease Virus (NDV) is specifically characterized in terms of biological activities. The present invention further discloses treatment of cancer by application of a clonal NDV strain to tumors. According to an... Agent: Winston & Strawn LLP Patent Department

20100113332 - Method of treating an inflammatory disease by double stranded ribonucleic acid: What is disclosed is the use of a formulation comprising double stranded ribonucleic acid (dsRNA) in the manufacture of a medicament for treating an inflammatory disease in a mammal and inhibiting production of tumor necrosis factor-α (TNF-α) in the mammal.... Agent: Nastech Pharmaceutical Company Inc Mdrna, Inc.

20100113334 - Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility: The present invention provides methods and compositions useful for reducing or preventing the transmission of nosocomial pathogens or an epidemic of nosocomial pathogens in a health care facility by decolonizing the gastro-intestinal tract, skin, or nasal passage of carriers and by preventing colonization of individuals at risk who may serve... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100113333 - Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections: The present invention is directed to antimicrobial compounds which have an affinity for binding bones. More particularly, the invention is directed to phosphonated derivatives of glycopeptide or lipoglycopeptide antibiotics. These compounds are useful as antibiotics for the prevention or treatment of bone and joint infections, especially for the prevention and... Agent: Roylance Abrams Berdo & Goodman, LLP

20100113336 - Therapeutic agent and method for ovulation disorder caused by luteinized unruptured follicle: A therapeutic agent for ovulation disorder of the present invention is characterized in comprising Granulocyte colony-stimulating factor; and that the ovulation disorder is caused by Luteinized Unruptured Follicle.... Agent: Fitch, Even, Tabin & Flannery

20100113337 - Method for reducing incidence or rate of development of skin cancers and related conditions: A method for treatment to reduce the incidence or rate of development of skin cancers and related conditions caused by or exacerbated by or associated with UVR-induced skin damage in an immuno-compromised subject, such as an organ transplant patient, comprises the step of administering to said subject an amount of... Agent: Polsinelli Shughart PC

20100113361 - Anti-ige vaccines: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention... Agent: Pharmacia & Upjohn

20100113342 - Antimicrobial kinocidin compositions and methods of use: The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γκo... Agent: Mcdermott, Will & Emery

20100113356 - Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors: A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides... Agent: Barnes & Thornburg LLP

20100113359 - Dimethylphenoxy modulators of viral protease activity and/or parasitic enzyme activity: The present invention relates to new dimethylphenoxy inhibitors of viral protease or parasitic enzymes, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100113347 - Exenatide and dalargin-based medicinal preparation for treating pancreatic diabetes: This invention relates to the field of medicine, in particular, to endocrinology. This invention offers a method of potentiation of a therapeutic effect of exenatide by administration of an effective quantity of exenatide in combination with an effective quantity of dalargin. Advantageous therapeutic effects of the invention include lowering of... Agent: Ladas & Parry LLP

20100113349 - Extracellular matrix-binding proteins from staphylococcus aureus: An isolated extracellular matrix-binding protein, designated as SdrE and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies... Agent: Stites & Harbison PLLC

20100113364 - Factor viii polymer conjugates: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.... Agent: Marshall, Gerstein & Borun (baxter)

20100113365 - Factor viii polymer conjugates: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.... Agent: Marshall, Gerstein & Borun (baxter)

20100113358 - Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta: The present disclosure provides compositions containing a leptin product and methods of clinical therapy and diagnostic methods for progressive cognitive disorders. According to one aspect, the described invention provides a method for treating a progressive cognitive disorder. According to another aspect, the described invention provides a method for improving resilience... Agent: Greenberg Traurig, LLP

20100113353 - Method and composition for inhibiting cardiovascular cell proliferation: Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the... Agent: Quine Intellectual Property Law Group, P.C.

20100113344 - Method of detection of nucleic acids with a specific sequence composition: This invention is a novel method for detecting and localizing specific nucleic acid sequences in a sample with a high degree of sensitivity and specificity. The method and novel compositions used in the method involve the use of Probe Nucleic Acids, the production of nucleic acid binding regions and the... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100113346 - Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method: i

20100113350 - Methods and compositions for modulating prostasin: The invention provides methods and compositions related to modulating prostasin.... Agent: Genentech, Inc.

20100113362 - Methods for inhibiting immune complex formation in a subject: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.... Agent: Fish & Richardson P.C.

20100113343 - Methods involving lef-1 regulation and use of lef-1 or compounds altering lef-1 signalling for treating or preventing diseases: The present inventions relates to the use of LEF-1 or functional fragments or homologs thereof, or enhancer or inducer of LEF-1 expression, activity or LEF-1 mediated signalling for the preparation of a pharmaceutical for preventing or treating all types of cytopenia of the myeloid or lymphoid lineage. In particular, the... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20100113341 - Methods of using corticotropin-releasing factor for the treatment of cancer: Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF) for a period of time exceeding 3 days.... Agent: Jones Day

20100113355 - Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90: An scFv peptide comprising a VH domain and a VL domain linked by an amino acid spacer is disclosed. The VH domain comprises a sequence with at least 80% sequence identity to the sequence of SEQ ID NO. 64. The VL domain comprises a sequence with at least 80% sequence... Agent: Mccarter & English, LLP Wilmington Basil S. Krikelis

20100113340 - Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof: The present invention is related to nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and uses thereof. More particularly, the present invention is related to a polypeptide being such adhesion factors and comprising an amino acid sequence, whereby the amino acid sequence... Agent: Morgan Lewis & Bockius LLP

20100113360 - Parathyroid hormone receptor activation and stem and progenitor cell expansion: The invention relates to methods for manipulating hematopoietic stem or progenitor cells, mesenchymal stem cells, epithelial stem cells, neural stem cells and related products through activation of the PTH/PTHrP receptor in neighboring cells.... Agent: Edwards Angell Palmer & Dodge LLP

20100113348 - Percutaneously absorbable preparation, process for production thereof and method for percutaneous absorption: A transdermal permeation preparation which comprises a base material which is a hydrophilic macromolecule which can swell after absorbing the water and/or water-containing alcohol and comprises a transdermal active ingredient which is in a molecular weight higher than 1000 Dalton and can dissolve or suspend in water and/or water-containing alcohol... Agent: Cheng Law Group, PLLC

20100113357 - Platelet-derived growth factor-responsive neural precursor cells and progeny thereof: This invention provides platelet-derived growth factor-responsive neural precursor (PRP) cells and methods of producing such cells in vivo or in vitro. These cells can further be used to generate neurons, oligodendrocytes and/or astrocytes.... Agent: Fish & Richardson P.C.

20100113345 - Preparation of low bleeding anticoagulant fusion protein and its use: Provided is an anticoagulant fusion protein comprising oligopeptide recognizable and cleavable by either factor XIa and factor Xa or thrombin and factor Xa. Also provided are the preparation method of the anticoagulant fusion protein and medicinal use thereof.... Agent: Fish & Richardson PC

20100113338 - Prophylactic or therapeutic agent for corneal/conjunctival disease: Disclosed is a novel composition for the treatment of a corneal/conjunctival disease. A prophylactic or therapeutic agent for a corneal/conjunctival disease comprising selenoprotein P as an active ingredient, more specifically a prophylactic or therapeutic agent for a corneal/conjunctival disease such as dry eye, keratoconjunctivitis sicca, superficial punctate keratopathy, corneal erosion... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100113352 - Retinol formulations and methods for their use: A composition for the treatment of skin comprises a non-emulsified, aqueous suspension of retinol. The composition may further include at least one protein species, and some proteins used in the composition include collagen and elastin. The composition may also include hyaluronic acid. The composition may also include one or more... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20100113339 - Serum albumin binding proteins with long half-lives: The present invention relates to amino acid sequences that are capable of binding to serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that... Agent: Wolf Greenfield & Sacks, P.C.

20100113354 - Therapeutic agent comprising vasohibin: A therapeutic agent containing Vasohibin for diabetic nephropathy, and a therapeutic agent containing Vasohibin for peritoneal sclerosis. Since the therapeutic agent containing Vasohibin of the present invention is a substance in which Vasohibin inhibits angiogenesis in an autocrine manner, the therapeutic agent is effective for inhibiting the progression of diabetic... Agent: Birch Stewart Kolasch & Birch

20100113351 - Therapeuting compositions comprising an rnai agent and a neurotrophic factor and methods of use thereof: The invention provides novel combination therapies for treating Huntington's disease which comprise a) BDNF or suitable fragments thereof and b) agents capable of causing inhibition of a gene responsible for the neurodegenerative disease. The invention provides nucleic acid sequences, methods, and systems suitable for applications of these combination therapies.... Agent: Kenneth J. Collier - C/o Kathy Illg Medtronic, Inc.

20100113363 - Use of glp-1 peptides: GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100113366 - Use of proline-rich peptide derived from hypothalamus for the manufacture of a medicament for the treatment and/or prophylaxis of cattle leucosis: P

20100113368 - Cholesterol lowering protein hydrolysates: The present invention relates to the production of novel peptides which have a length of between 4 and 8 amino acids and comprises the amino acid sequence -Xaa-Xbb-Xcc-Xdd-, whereby Xaa and Xdd can be His (H), Arg (R) or Lys (K), and Xbb and Xcc can be Pro (P) or... Agent: Nixon & Vanderhye, PC

20100113367 - Peptide-cytotoxic conjugates: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.... Agent: Alan F. Feeny, Esq.

20100113369 - Means for preventing and treating cellular death and their biological applications: Inhibitors for preventing, blacking/silencing caspase-2 activity in cell death.... Agent: Nixon & Vanderhye, PC

20100113370 - Methods and compounds for modulating inflammatory processes: Provided is a method of treating a patient having an inflammatory disease by using a compound which inhibits the ABCC4-mediated release of leukotrienes, a medicament containing such compound and methods for screening such compounds.... Agent: Howrey LLP-ca

20100113371 - Derivatives of pentose monosaccharides as anti-inflammatory compounds: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases, for example, bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. The present invention... Agent: Ranbaxy Inc.

20100113373 - Antiviral supplement formulations: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides... Agent: Merchant & Gould PC

20100113372 - Method for preparing kaempferol-3-0-rutinoside and composition of skin external application comprising thereof: Disclosed is a method for the preparation of kaempferol-3-O-rutinoside and a composition of a skin external application comprising kaempferol-3-O-rutinoside as an active ingredient. The method for isolating kaempferol-3-O-rutinoside through hydrolysis uses an enzyme or microbe that removes the sugar selectively from kaempferol-3-O-rutinoside glycosides in a plant extract. Disclosed also is... Agent: Sughrue Mion, PLLC

20100113374 - Methods and related compositions using specific flavonoids and indanes to reduce weight and inhibit lipase, alpha-amylase and alpha-glucosidase activity in mammals: The present invention relates generally to methods and related compositions using flavonoids and/or indanes extracted from the stems and leaves of C. quadrangularis to reduce weight and inhibit lipase, α-amylase and α-glucosidase activity in mammals. By example and not by way of limitation, embodiments of the present disclosure, a composition... Agent: Greenberg Traurig LLP (la)

20100113375 - Methods and related compositions using specific flavonoids and indanes to reduce weight and inhibit lipase, alpha-amylase and alpha-glucosidase activity in mammals: The present invention relates generally to methods and related compositions using flavonoids and/or indanes extracted from the stems and leaves of C. quadrangularis to reduce weight and inhibit lipase, α-amylase and α-glucosidase activity in mammals. By example and not by way of limitation, embodiments of the present disclosure, a composition... Agent: Greenberg Traurig LLP (la)

20100113376 - Process for dosing self-emulsifying drug delivery systems: The present invention provides process for dosing a self-dispersing drug delivery system comprising an active compound, said process comprising the step of using a dosage dispenser to dose a defined amount of said self-dispersing drug delivery system comprising an active compound and a dosage dispenser containing a self-dispersing drug delivery... Agent: Manelii Denison & Selter PLLC

20100113378 - Compositions and methods for treating and preventing cancer using analogs of vitamin d: Disclosed are compositions and methods used to treat and/or prevent cancer and metabolic diseases, such as psoriasis. In one aspect, the present invention pertains to the use of cross-linking analogs of vitamin D and its metabolites employed for the treatment of prostate cancer.... Agent: Burns & Levinson, LLP

20100113377 - Method of treatment using alpha-1-adrenergic agonist compounds: Methods for treating or preventing cardiomyopathy in a subject by administering an al adrenergic receptor agonist, wherein the treatment does not result in increased blood pressure are provided.... Agent: King & Spalding LLP

20100113559 - Chitosan based polymer conjugate and a method for producing the same: The present invention relates to a conjugate of chitosan and polyamine polymer that is useful for transferring a desired gene medicine into cells, and a method for preparing the same. In particular, the present invention relates to a double conjugate that is prepared by 1 in king poly-L-arginine to low... Agent: Summa, Additon & Ashe, P.A.

20100113560 - Compositions and methods for treating hematopoietic malignancies: Described herein are compositions and methods for the prevention and treatment of hematopoietic malignancies. The compositions are miRNAs and associated nucleic acids.... Agent: Rosetta-genomics C/o Polsinelli Shughart PC

20100113558 - Compounds and methods: A small nucleic acid molecule that down-regulates expression of Wrap53 gene via RNA interference (RNAi), wherein at least one strand of said small nucleic acid molecule is about 15 to about 30 nucleotides in length; and wherein at least one strand of said small nucleic acid molecule comprises a nucleotide... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100113557 - Method for prevention of tumor: The present invention provides a method for inhibiting a tumor, which comprises suppressing the expression of HERC2. In one embodiment of the present invention, the suppression of HERC2 is induced by the expression of BRCA1.... Agent: Dickstein Shapiro LLP

20100113563 - Method for treating pain with a calmodulin inhibitor: The present invention relates to the use of Ca2+/CaM-dependent protein kinase II (CaMKII) inhibitors alone and in combination with opiate analgesics for treating pain, in particular chronic pain. Methods for reducing or reversing tolerance, dependence, and opioid-induced hyperalgesia are also provided.... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20100113561 - Microrna molecules: In Caenorhabditis elegans, lin-4 and let-7 enclode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as “small temporal RNAs” (stRNAs). We show that many more 21- and 22-nt expressed... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100113564 - Rna interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin... Agent: Merck

20100113562 - Therapeutic targets and molecules: The invention provides methods and compositions for treating or preventing inflammation or an inflammatory condition in a subject, comprising administering to the subject an effective amount of at least one antagonist of one or more miRNA upregulated in inflammatory disease conditions and response to allergen challenge. The invention also provides... Agent: Pearl Cohen Zedek Latzer, LLP

20100113571 - Compounds having anti-adhesive effects on cancer cells: Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3′->P5′ thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells.... Agent: King & Spalding LLP

20100113576 - Device and method for processing or treating surfaces by means of a dry ice granulate: The invention relates to an apparatus for surface processing or surface treatment by means of dry ice granulate, with a reservoir for receiving a dry ice medium, in particular dry ice pellets, an inlet for the feed of a propellant medium, an outlet for the supply of a mixture of... Agent: Polsinelli Shughart PC

20100113565 - Immunostimulatory combinations and methods: The invention provides immunostimulatory compositions and methods of enhancing TLR8-mediated biological activity. Generally, the immunostimulatory compositions include a TLR8 agonist and an immunostimulatory oligonucleotide in an amount effective to enhance TLR8-mediated biological activity. The invention also provides methods of inducing TLR8-mediated biological activity in immune cells. Generally, the methods include... Agent: 3m Innovative Properties Company

20100113569 - Isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells: An isolated DNA sequence that corresponds to a region of the human A33 gene promoter from base pair −105 to base pair +307, able to control the expression of a heterologous gene of interest, that may be used in conjunction with any other regulatory sequence, including sequences responsive to stress... Agent: Fish & Richardson PC

20100113577 - Isolated nucleic acid molecules corresponding to micro rna 145 (mirna-145) and their use in treating colon cancer: Provided herein are isolated nucleic acid molecule corresponding to miR145 that are useful in treating colon cancer. The disclosed miR145 nucleic acids specifically bind the 3′ UTR within endogenous IRS-I such as to suppress or inhibit colon cell proliferation.... Agent: Merck

20100113575 - Method for detecting autoprocessed, secreted pcsk9: The present invention provides a method for detecting autoprocessed, secreted PCSK9, a protein involved in cholesterol homeostasis, and for effectively identifying compounds that inhibit autocleavage and secretion from cells. The disclosed method involves the insertion of an epitope tag into a PCSK9 expression construct immediately C-terminal to the pro domain... Agent: Merck

20100113568 - Methods for binding lewis y antigen: A method for binding Lewis Y antigen of a subject, comprising administering to the subject an effective amount of nucleotide sequence encoding N-terminal lectin-like domain of thrombomodulin (TMD1), or its analogues; and a method of detecting cancer cells, Gram-negative bacteria or LPS which over-express the Lewis Y antigen in a... Agent: Wpat, PC Intellectual Property Attorneys

20100113573 - Modulation of hif1 beta expression: Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20100113566 - Nucleic acid for treatment or prevention of immunodeficiency virus infection: A nucleic acid comprising a transcription regulation sequence whose transcription is induced by a trans-acting factor of a human immunodeficiency virus and a gene encoding a polypeptide having an endoribonuclease activity specific to single-stranded RNA, wherein the gene is located in such a position that the expression of the gene... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100113572 - Photoreactive ru (ii) complexes anchored on oligonucleotides, method for obtaining them and use thereof: Photoreactive Ru (II) complexes are anchored on a G-containing oligonucleotide, e.g. compound 1. The method for obtaining them and their use, includes targeting specific nucleotide sequences that become photocrosslinked to the photoreactive Ru (II) complex anchored to the G-containing oligonucleotide.... Agent: Merchant & Gould PC

20100113574 - Polynucleotides for enhancing expression of a polynucleotide of interest: The present invention relates to polynucleotides comprising a first nucleic acid sequence for a chromatin element, which is capable of enhancing expression, and at least one second nucleic acid sequence comprising a curved origin motif. Furthermore, the invention relates to a host cell, a non-human transgenic organism, a vector and... Agent: Birch Stewart Kolasch & Birch

20100113570 - Prevention and treatment of post-operative cognitive dysfunction: Methods for the use of uncompetitive NMDA receptor antagonist(s) in inhalational anesthesia are provided herein.... Agent: Wolf Greenfield & Sacks, P.C.

20100113578 - Prevention of and countermeasures against mitochondrial disease: The present invention relates to an agent containing L-arginine, 0.2 to 20 parts by weight of L-ascorbic acid per 1 part by weight of L-arginine, and, if desired, at least one selected from the group consisting of ribonucleic acids, ribonucleotides and ribonucleosides. The agent can treat mitochondrial disease which shows... Agent: Oliff & Berridge, PLC

20100113567 - Recombinant vsv for the treatment of tumor cells: The present invention relates to compositions and methods for the treatment of tumor and/or malignant and/or cancerous cells. The present invention provides VSV vectors comprising nucleic acid encoding a cytokine, such as interleukin or interferon, or a suicide gene, such as thymidine kinase, or other biological protein, such as heat... Agent: Darby & Darby P.C.

20100113379 - Camp dependent induction of autophagy: The present invention relates to the induction of autophagy via mTOR independent pathways which modulated intracytosolic cAMP levels. In some embodiments, autophagy may be induced in a cell by reducing intracytosolic cAMP levels, for example using a cAMP antagonist, such as clonidine. This may be useful, for example in the... Agent: Klarquist Sparkman, LLP

20100113380 - P2x7 antagonists to treat affective disorders: The present invention provides methods to treat mood disorders and anxiety disorders using antagonists of the P2X7 receptor and pharmaceutical compositions thereof, or combinations.... Agent: Robert Deberardine D-377/ap6a-1

20100113381 - Effective treatment of esophogeal adenocarcinoma using triciribine and related compounds: The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a... Agent: Morgan Lewis & Bockius LLP

20100113382 - Combined use of dipeptidyl peptidase 4 inhibitor and sweetener: The present invention provides a novel therapeutic or preventive method, a pharmaceutical composition and use thereof, that exhibit superior anti-obesity effects (body weight-reducing (losing) effects and/or body fat mass-reducing effects). Specifically, the present invention provides a pharmaceutical composition comprising the combination of a dipeptidyl peptidase 4 inhibitor and a sweetener... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100113384 - Bacterial endotoxin for the prevention of metabolic disorders and bacterial infections: The invention provides compositions and methods for preventing a metabolic disorder or bacterial infection in a subject, the composition comprising a bacterial endotoxin.... Agent: Drinker Biddle & Reath (dc)

20100113383 - Bifidobacterial gene sequences and their use: This invention provides nucleic acids and proteins involved in oligosaccharide modification in the species Bifidobacteria. The invention provides methods for utilizing the proteins of the invention to generate human milk oligosaccharides or oligosaccharide mimics. The invention also provides compositions containing the human milk oligosaccharides or oligosaccharide mimics and methods for... Agent: Townsend And Townsend And Crew, LLP

20100113385 - Complex combining an organic silicon derivative with hyaluronic acid calibrated fragments, for preventive and repairing action of cutaneous damages: The invention also concerns the use of such a complex in the prevention or the repair of cutaneous damages.... Agent: Volpe And Koenig, P.C.

20100113386 - N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof: The present invention relates to N-Benzyl-Substituted Pyridyl Porphyrin Compounds, compositions comprising an effective amount of an N-Benzyl-Substituted Pyridyl Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction, urinary incontinence, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100113388 - 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient: (wherein all symbols have the same meanings as described in the specification), a pharmaceutically acceptable salt thereof or a cyclodextrin clathrate thereof. Since the compound represented by formula (I) binds to EP2 subtype among PGE receptor strongly, it is useful for preventive and/or treatment for immune diseases, allergic diseases, neuronal... Agent: Sughrue-265550

20100113387 - Fatty acids for use as a medicament: The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin... Agent: Cantor Colburn, LLP

20100113389 - Method of treating graft-rejection using dextran sulfate: The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament... Agent: Young & Thompson

20100113390 - Oligosaccharides derived from fucoidan: The present invention provides a fucoidan-derived low molecular weight compound with a good quality of taste, which has a specified structure and function and is free from problems in absorption, antigenicity, uniformity, an anticoagulant activity and so on, which problems arise when developing fucoidan, a sulfated polysaccharide having an extremely... Agent: Drinker Biddle & Reath (dc)

20100113391 - Bicyclic heterocyclic compound: The inventors have eagerly investigated P2Y12 inhibitors. As a result, the inventors have found that a bicyclic heterocyclic compound such as quinazolinedione, isoquinolone, and the like having an amino group substituted with lower alkyl, cycloalkyl, or lower alkylene-cycloalkyl at the specific position exhibits an excellent platelet aggregation inhibitory action, thereby... Agent: Sughrue-265550

20100113393 - Boronic acid salts: Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100113392 - Methods of using saha and bortezomib for treating multiple myeloma: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20100113394 - Low dosage forms of risedronate or its salts: Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or... Agent: Fitzpatrick Cella Harper & Scinto

20100113395 - Low dosage forms of risedronate or its salts: Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or... Agent: Fitzpatrick Cella Harper & Scinto

20100113396 - Method and composition for potentiating an opiate analgesic: Composition and methods of treating pain and reducing or reversing tolerance to opiate analgesics are disclosed. The composition and method utilize an opiate analgesic and an endothelin antagonist as active agents to treat pain in mammals, including humans.... Agent: Marshall, Gerstein & Borun LLP

20100113397 - Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity: Novel phosphonate compounds are described. The compounds have activity as neuraminidase inhibitors against wild-type and H274Y mutant of H1N1 and H5N1 viruses. The present disclosure also provides an enantioselective synthetic route to known neuraminidase inhibitors oseltamivir and the anti-flu drug Tamiflu®, as well as novel phosphonate compounds, via D-xylose. Another... Agent: Greenberg Traurig LLP (la)

20100113398 - Treatment and/or prevention of non-viral epithelial damage: There is provided the use of an inhibitor of phosphate transporter activity for the manufacture of a medicament for the prevention and/or treatment of non-viral damage to an epithelium, or of a condition caused or characterised by such damage. The inhibitor of phosphate transporter activity may optionally be a phosphono-carboxylic... Agent: Wilmerhale/boston

20100113400 - 9-aminomethyl substituted minocycline compounds: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and... Agent: Mccarter & English, LLP Boston

20100113401 - Methods for synthesizing and purifying aminoalkyl tetracycline compounds: Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100113399 - Salts and polymorphs of a tetracycline compound: Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100113402 - Compositions for treatment of inflammatory diseases: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or... Agent: Dunlap Codding, P.C.

20100113403 - Compositions containing compounds having steroid structure and their use for inducing the proliferation and differentiation of stem cells of the organism: Use of a mixture of phytosterols, selected from the group comprising: brassicasterol (Delta 5-C22 unsaturated); campesterol; campestanol; stigmasterol (Delta 5-C22 unsaturated); Delta 5-C23-stigmastadienol; clerosterol (Delta 8-C25 unsaturated); Beta-sitosterol; sitostanol; Delta 5-venasterol (Delta 5-C24 unsaturated); Delta 5-C24-stigmastadienol (Delta 5-C24 diene unsaturated); Delta 7-stigmastenol; 24-methylene-cycloartenol; gramisterol; 24-methylcholest-7-enol; isofucosterol; Delta 7-avenasterol (Delta 7-C24... Agent: Arent Fox LLP

20100113404 - Anti-angiogenic activity of 2-methoxyestradiol analogs in combination with anti-cancer agents: The present invention relates generally to methods and compositions for treating diseases characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering antiangiogenic agents in combination with anti-cancer agents. More specifically, the present invention relates to methods and compositions for treating diseases characterized by abnormal cell proliferation and/or... Agent: King & Spalding

20100113405 - Methylindazole modulators of 5-ht3 receptors: The present invention relates to new methylindazole modulators of 5-HT3 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100113407 - Androgen treatment in females: The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75... Agent: Beem Patent Law Firm

20100113406 - Use of glucocorticoids for treatment of congestive heart failure: Disclosed are methods comprising administering a dosage form comprising a pharmaceutical carrier and at least one glucocorticoid to a subject suffering from congestive heart failure, wherein the at least one glucocorticoid is present in the dosage form in an amount effective to ameliorate aspects of the congestive heart failure. Also... Agent: Durect Corporation Thomas P. Mccracken

20100113408 - 21-substituted progesterone derivatives as new antiprogestational agents: In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine... Agent: Leydig, Voit & Mayer, Ltd.

20100113409 - Hydrochloride salt of 5-[3-(3-hydroxyphenoxy) azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide: This invention relates to the hydrochloride salt of 5-[3-{3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenyl-hexanamide or derived form thereof and its use as a medicament.... Agent: Pfizer Inc. Patent Department

20100113412 - Imidazo[1,2-a]pyridines and their use as pharmaceuticals: in which R, R1 to R4 and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100113413 - Mapk/erk kinase inhibitors:

20100113410 - Pyrazolopyrimidine derivative: Solution The present invention provides a pyrazolopyrimidine compound represented by the formula (1) having various substituents which inhibits the ATPase activity of HSP90 and which has antitumor activity, an HSP90 inhibitor comprising the compound represented by the formula (1), a medicament comprising the compound represented by the formula (1), an... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100113411 - Selected cgrp antagonists, processes for preparing them and their use as pharmaceutical compositions: the tautomers, diastereomers, enantiomers, hydrates, mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100113414 - Thiazolyl-dihydro-indazoles: e

20100113415 - Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer:

20100113416 - Janus kinase inhibitors for treatment of dry eye and other eye related diseases: Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.... Agent: Fish & Richardson PC

20100113417 - Substituted spiroamine compounds: In which m, n, o, p, Q, r, s, t, R1, R2, R3, R4a, R4b, R5a, R5b, R6a, R6b, R7, R8, R9, R10 and R11 have defined meanings; a process for the preparation of such compounds, pharmaceutical compositions containing such compounds and the use of substituted spiroamines for the treatment... Agent: Crowell & Moring LLP Intellectual Property Group

20100113419 - Cgrp receptor antagonists: (where variables R1, R2, R3, R4, A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention... Agent: Merck

20100113418 - Heterocyclic compound: h

20100113420 - Pyrrolopyrimidine derivatives as jak3 inhibitors: Pyrrolopyrimidine derivatives of Formula (I) that are useful as JAK3 kinase inhibitors.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100113421 - Non-nucleoside reverse transcriptase inhibitors: Compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein X, R1, R2, R3, R4 and R5 are defined herein. The compounds of Formula (I) and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the... Agent: Merck

20100113422 - Pyrimido [4,5-d] azepine derivatives as 5-ht2c agonists: or a pharmaceutically acceptable salt thereof wherein the variables R1, R2, R3a, R3b, R3b, R3d, and R100 are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a 5-HT2c receptor-mediated disorders with a compound of formula (I) or... Agent: Pfizer Inc. Patent Department

20100113423 - Modulators of aldehyde dehydrogenase and methods of use thereof: The present disclosure provides compounds that function as modulators of aldehyde dehydrogenase (ALDH) enzymatic activity, as well as compositions and formulations comprising the compounds. The present disclosure provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20100113424 - N-benzyl pyrrolidine derivatives: e

20100113427 - Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions: The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of alcohol dependence and other dopamine pathway-associated disorders or conditions. Preferably, the pharmaceutical compositions of the present invention comprise amounts of the 5-HT3 receptor antagonist ondansetron... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20100113426 - Intranasal benzodiazepine compositions: A pharmaceutical composition for intranasal administration to a mammal. The pharmaceutical composition comprises an effective amount of a benzodiazepine or pharmaceutically acceptable salt thereof; and a nasal carrier. In some embodiments, the pharmaceutical composition when administered intranasally produces a rapid physiological response. Pharmaceutical compositions may also include at least one... Agent: Goodwin Procter LLP Patent Administrator

20100113425 - Pyrrolobenzodiazepines: p

20100113428 - Diazabicyclic aryl derivatives as cholinergic receptor modulators: This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse... Agent: Birch Stewart Kolasch & Birch

20100113429 - Inhibitors of ftsz and uses thereof: The invention relates to inhibitors of FtsZ polymerization and uses thereof.... Agent: Ballard Spahr LLP

20100113430 - Thioxanthene derivates useful to treat infectious diseases: The present invention is directed to certain thioxanthene derivatives and phenothiazine derivatives suitable for use as anti-infective agents, in particular, for treatment of infectious diseases. The invention furthermore relates to compositions comprising said anti-infective agents.... Agent: The Nath Law Group

20100113431 - N-methyl piperazine modulators of h1 receptor: The present invention relates to new N-methyl piperazine modulators of H1 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100113432 - Phenothiazine modulators of d2 receptors and 5-ht2 receptors: The present invention relates to new phenothiazine modulators of D2 receptor activity and/or 5-HT2 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100113433 - N-substituted thiomorpholine derivatives as the inhibitors of dipeptidyl peptidase iv and the pharmaceutical uses thereof: The present invention relates to N-Substituted thiomorpholine compounds of formula I, the possible isomers, the pharmaceutically acceptable salts, the solvates, the hydrates or the prodrugs thereof as inhibitors of dipeptidyl peptidase IV (DPP-IV); and to a method for preparing the compounds of formula I, pharmaceutical compositions comprising the compounds of... Agent: Macmillan Sobanski & Todd, LLC

20100113434 - Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease,... Agent: Swiss Tanner, P.C. P.o. Box 1749

20100113435 - Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1: The present invention relates to compounds with the formula (II) and also to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1... Agent: Foley And Lardner LLP Suite 500

20100113436 - Dispiro tetraoxane compounds and their use in the treatment of malaria and/or cancer: A compound having the formula (I) wherein ring A represents a substituted or unsubstituted monocyclic or multicyclic ring; m=any positive integer; n=0-5; X=CH and Y=—C(O)NR1R2, —NR1R2 or —S(O)2R4, where R1, R2 and R4 are each individually selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100113437 - Active compound combinations having insecticidal and regular, utility: The novel active compound combinations comprising compounds of the formula (I) or (II) and active compounds (1) to (30) listed in the description have very good insecticidal and acaricidal properties.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100113438 - Class of histone deacetylase inhibitors: New histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, CH—NR3R4, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl, R11,... Agent: Mccormick, Paulding & Huber LLP

20100113439 - Antifungal agents: Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates... Agent: Covington & Burling, LLP Attn: Patent Docketing

20100113440 - Pyrimidine substituted macrocyclic hcv inhibitors: Compounds of the Formula (I) including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.... Agent: Philip S. Johnson Johnson & Johnson

20100113441 - Substituted imidazopyrimidines and triazolopyrimidines: The invention relates to substituted imidazopyrimidines and triazolopyrimidines, to methods for the production thereof, and to the use of same for producing medicaments for the treatment and/or prophylaxis of diseases, especially haematological diseases, preferably leucopenia and neutropenia.... Agent: Edwards Angell Palmer & Dodge LLP

20100113442 - Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases: The present invention relates to a compound according to formula (I), wherein X and Y are either C and N or N and C; Z is CH2, CH2—CH2, CH2—NH, or NH; R1 is halogen, or R1 is alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, cycloalkyl, alkoxycarbonyl, aryl, all of which are optionally... Agent: Birch Stewart Kolasch & Birch

20100113443 - Liquid formulations of phospholipase enzyme inhibitors: The present invention relates to liquid formulations of inhibitors of phospholipase enzymes, such as cytosolic PLA2, compositions containing the same and processes for manufacture thereof.... Agent: Wyeth LLC Patent Law Group

20100113445 - Chemical compounds: The present invention relates to dianilinopyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such dianilinopyrimidine derivatives are useful in the treatment of diseases associated with inappropriate Wee1 kinase activity.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100113446 - Hydantoin compounds: The invention relates to the use of hydantoin compounds useful for treating or preventing autoimmune disorders. The present invention also provides compositions and uses thereof.... Agent: Myers Bigel Sibley & Sajovec

20100113444 - Prolyl hydroxylase inhibitors: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I), (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100113447 - Triazole compounds that modulate hsp90 activity: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to... Agent: Foley & Lardner LLP

20100113448 - Oxazolidinone derivative having inhibitory activity on 11beta-hydroxysteroid dehydrogenase type 1: e

20100113449 - Fused heterocyclic compounds as ion channel modulators:

20100113450 - Agent for preventing and alleviating wrinkles: wherein R1 and R2 independently represent any of a hydrogen atom, an alkyl group having 1 to 3 carbon atoms, a benzyloxycarbonyl group, a cyclohexyl group, a cyclohexanemethyl group, a cyclohexanecarbonyl group, a guanidino group formed with nitrogen atom in the formula (1), an ureido group formed with nitrogen atom... Agent: Rankin, Hill & Clark LLP

20100113451 - Novel preventive and/or therapeutic agent for diabetic neuropathy: The present invention relates to an agent for preventing and/or treating diabetic neuropathy comprising a 2-[(substituted-inden-7-yloxy)methyl]morpholine of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The invention is useful for providing an excellent agent for preventing and/or treating diabetic neuropathy, and particularly useful for providing... Agent: Fitzpatrick Cella Harper & Scinto

20100113452 - Compounds for treating pulmonary hypertension: The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing pulmonary hypertension comprising small molecule heterocyclic pharmaceuticals, and more particularly, substituted pyridines and pyridazines optionally combined with at least one additional therapeutic agent.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100113455 - Method of reducing intraosseous hypertension: A method of treating bone pain caused by osteoarthritis by administering to a patient an effective amount of a composition containing a bone edema medication, such as a vasoactive medication or phosphodiesterase inhibitor, including a PDE-5 inhibitor.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20100113454 - Pyrrolotriazine kinase inhibitors: m

20100113453 - Sublingual formulations of d-cycloserine and methods of using same: The invention provides methods and compositions for treating anxiety-related disorders in a subject. The methods include sublingually administering D-cycloserine to a subject with the anxiety-related disorder, either alone or in combination with extinction training.... Agent: Jason P. Mcdevitt

20100113456 - Therapeutic agent for corneal disease: A therapeutic agent for a corneal disease comprising irsogladine or a salt thereof as an active ingredient. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100113457 - Novel pyridazine derivatives: The present invention relates to novel pyridazine derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein R1 is hydrogen, C1-C6alkyl, C1-C6haloalkyl or C3-C6cycloalkyl; R2 is halogen, nitro, cyano, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, C1-C4alkylthio or C1-C4haloalkylthio; R3 is an optionally substituted aryl; R4 is... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100113458 - Imidazopyridazinecarbonitriles useful as kinase inhibitors: e

20100113459 - Gene polymorphisms as predictors of tumor progression and their use in cancer therapy: The invention provides compositions and methods for determining the likelihood of successful treatment with a pyrimidine based antimetabolite chemotherapy drug and a platinum based chemotherapy drug, such as 5-FU/oxaliplatin. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism... Agent: Foley & Lardner LLP

20100113460 - Organic compounds: Disclosed are compounds having the ability to inhibit cytochrome P450 2A6, 2A13, and/or 2B6 and tobacco products comprising them. Also disclosed are pharmaceutical compositions comprising them.... Agent: Parfomak, Andrew N. Norris Mclaughlin & Marcus Pa

20100113463 - Pteridinone derivatives for use as stearoyl coa desaturase inhibitors: s

20100113462 - Substituted benzoylamino-indan-2-carboxylic acids and related compounds: wherein in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100113461 - Substituted heterocyclic compounds: e

20100113464 - Novel pyridazine derivatives: The present invention relates to novel pyridazine derivatives of formula I as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein R1 is hydrogen, C1-C6alkyl, C1-C6haloalkyl or C3-C6cycloalkyl; R2 is an optionally substituted heteroaryl; R3 is an optionally substituted aryl; and R4 is hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100113465 - 7-azaspiro[3.5]nonane-7-carboxamide compounds: Provided herein are 7-azaspiro[3.5]nonane-7-carboxamide compounds and the pharmaceutically acceptable salts of such compounds useful in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity, conditions including including acute pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, cancer and cancer pain, fibromyalgia, rheumatoid arthritis, inflammatory bowel disease,... Agent: Pfizer Inc Mary J Hosley

20100113466 - Oxazole-pyridazine-oxazole alpha-helix mimetic: There are provided alpha helix scaffolds mimicking i, i+3/i+4, i+7 or i+11 residues having the general structure oxazole-pyridazine-piperidine or oxazole-pyridazine-oxazole. The common pyridazine heterocycle originates from substituted or unsubstituted dimethyl 1,2,4,5-tetrazine-3,6-dicarboxylate. These scaffolds are synthetic counterparts of amphiphilic alpha helices having a hydrophilic face along one side and a hydrophobic... Agent: Townsend And Townsend And Crew, LLP

20100113467 - Organic compounds: e

20100113469 - Combination therapy for the treatment-of lower urinary tract symptoms: This invention concerns compositions for the treatment of Lower Urinary Tract Symptoms (LUTS), and especially LUTS which results from benign prostatic hypertrophy. The compositions of the invention comprise a Beta-3 agonist described below, optionally in combination with a 5-alpha reductase inhibitor, or an NK-1 antagonist or an alpha-1 adrenergic antagonist... Agent: Merck

20100113468 - Quinazoline derivatives as kinase inhibitors: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the... Agent: Townsend And Townsend And Crew, LLP

20100113470 - Bcr-abl variants: A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct.... Agent: Foley & Lardner LLP

20100113472 - Compounds for the treatment of osteoporosis and cancers: Methods are provided for the treatment of osteoporosis and multiple myeloma, using 3-imidazoyl-pyrazolo[3,4-b]pyridine compounds.... Agent: Townsend And Townsend And Crew, LLP

20100113473 - Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor: t

20100113474 - Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine: A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents,... Agent: Wyeth LLC Patent Law Group

20100113475 - Pyrazolylaminopyridines as inhibitors of fak: c

20100113471 - 2-aminoaryloxazole compounds as tyrosine kinase inhibitors: The present invention relates to novel compounds selected from 2-aminoaryloxazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic and degenerative disorders. More particularly, these compounds are potent... Agent: Foley And Lardner LLP Suite 500

20100113476 - Chemical linkers with single amino acids and conjugates thereof: The present disclosure provides drug-ligand conjugates that are potent cytotoxins and include a linker between the drug and ligand where the linker has a single amino acid. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.... Agent: Medarex C/o Darby & Darby P.C.

20100113477 - Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof: The present invention provides aryl- or heteroaryl-diketo acid compounds effective to inhibit an activity of a Mycobacterial malate synthase enzyme or to inhibit a malate synthase activity in other bacteria having the enzyme. The compounds may be phenyl-naphthyl-, or thienyl-substituted diketo acids and carboxylate derivatives thereof. Also provided are methods... Agent: Benjamin Aaron Adler Adler & Associates

20100113478 - Indolone modulators of 5-ht3 receptor: The present invention relates to new indolone modulators of 5-HT3 receptor, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100113479 - Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists: The present invention is directed to novel processes for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives, useful as glucose dependent insulinotropic receptor agonist, for the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.... Agent: Philip S. Johnson Johnson & Johnson

20100113480 - Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists: The present invention is directed to novel processes for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives, useful as glucose dependent insulinotropic receptor agonist, for the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.... Agent: Philip S. Johnson Johnson & Johnson

20100113481 - Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents: The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A, wherein such agents are... Agent: Alcon

20100113483 - Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions: The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of obsessive, impulsive and compulsive behavioral activities and other dopamine pathway-associated disorders or conditions. Preferably, the pharmaceutical compositions of the present invention comprise amounts of the... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20100113482 - Novel compounds for treating mental disorders, and preparation and uses thereof: The present invention relates to a compound of formula (I), an optical isomer or a pharmaceutically acceptable salt thereof, its preparation and uses, wherein R is defined as herein. Such compounds can be presented as an optical isomer or a racemic mixture. The compounds can be metabolized in vivo to... Agent: The Webb Law Firm, P.C.

20100113485 - Piperidinylamino-thieno[2,3-d] pyrimidine compounds: The invention relates to 5-HT receptor modulators, particularly 5-HT2B antagonists. Novel piperidinylamino-thieno[2,3-d]pyrimidine compounds represented by Formula I, II and III, and uses thereof for treating conditions including pulmonary arterial hypertension, congestive heart failure, and hypertension.... Agent: Goodwin Procter LLP Patent Administrator

20100113484 - Treating agent of uropathy: Disclosed is a treating agent of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria in benign prostatic hyperplasia or urolithiasis, which comprises a compound having PDE9-inhibiting activity as the active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100113486 - Use of pde7 inhibitors for the treatment of movement disorders: A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100113487 - Pyrimidinone derivatives and methods of use thereof: The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disease, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.... Agent: Merck Patent Department (k-6-1, 1990)

20100113488 - Macrocyclic factor viia inhibitors useful as anticoagulants: or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, C, D, L, M, W, Z1, Z2, Z3, Z4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be... Agent: Louis J. Wille Bristol-myers Squibb Company

20100113489 - Modulators of chemokine receptor activity, crystalline forms and process:

20100113490 - Substituted pyrimidine ether compounds and use thereof: The compounds of formula I show high insecticidal activities for imagoes, larvae and nits of harmful acari and insects in the agricultural, civil and zoic fields, especially show excellent insecticidal activities for harmful acari such as Tetranychus cinnabarinus. Good effects can be obtained at very low dose. The compounds also... Agent: Smith, Gambrell & Russell

20100113491 - Synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (bpu) sulfur analogs: A novel series of BPU analogues were synthesized and evaluated for antitumor activity. In particular, BPU sulfur analogues 6n and 7d were shown to possess up to 10-fold increased potency, when compared to compound 1, against cancer cell lines. 6n was more effective than compound 1 in causing apoptosis of... Agent: Pearl Cohen Zedek Latzer, LLP

20100113492 - Substituted aminopyrimidines as cholecystokinin-1 receptor modulators: Certain novel substituted aminopyrimidines are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.... Agent: Merck

20100113493 - (pyrrolidin-2-yl)phenyl derivatives: wherein R1 is (C1-4)alkyl, halo(C1-4)alkyl, (C1-4)alkyloxy, or halo(C1-4)alkyloxy; R2 is H, (C1-4)alkyl, halo(C1-4)alkyl, (C1-4)alkyloxy, halo(C1-4)alkyloxy or halogen; R3 is H, (C1-4)alkyl or halo(C1-4)alkyl; R4 is H, (C1-4)alkyl or halo(C1-4)alkyl; R5 is H, (C1-4)alkyl or halo-(C1-4)-alkyl; or R4 and R5, when bonded to the same carbon atom, can together with the... Agent: Organon Usa, Inc. C/o Merck

20100113494 - 13,13a-dihydroberberine derivatives for use in pharmaceutical compositions: The present invention provides 13,13a-dihydroberberine derivatives or their physiologically acceptable salts represented by the following formula, pharmaceutical compositions comprising the same, and uses thereof. The 13,13a-dihydroberberine derivatives have an activity of promoting glucose absorption in muscle cells, and the whole animal tests show that the present compounds have effects on... Agent: Baker & Hostetler LLP

20100113497 - Gaba conjugates and methods of use thereof: In one aspect, the present invention provides a composition of a covalent conjugate of a GABA analog with a drug. In another aspect, the present invention provides methods for treating pain and neurological disorders using the conjugates of GABA analogs.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100113495 - Pharmaceutical compositions comprising an opioid receptor antagonist and methods of using same: The present invention features compositions for intranasal administration comprising an opioid receptor antagonist. The invention also features methods of using such compositions in the treatment of various diseases and disorders, such as the treatment of alcoholism. In certain embodiments, the opioid receptor antagonist is naltrexone or a pharmaceutically acceptable salt... Agent: Goodwin Procter LLP Patent Administrator

20100113496 - Piperidine modulators of vmat2: The present invention relates to new piperidine modulators of VMAT2, nicotinic acetylcholine receptors, and/or μ-opioid receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group, LLC

20100113498 - Novel vinblastine derivatives, their preparation, use and pharmaceutical compositions comprising the said derivatives: The invention provides vinblastine derivatives represented by the following formula 1 or their physiologically acceptable salts, their preparation, use and pharmaceutical compositions comprising the said derivatives. The said vinblastine derivatives show inhibiting activities against tumor cell lines and can be used as medicaments for treating malignant tumors.... Agent: Nixon & Vanderhye, PC

20100113499 - Medicament for the treatment of endometriosis: The use of a dopamine agonist in the manufacture of a medicament for the treatment or prevention of endometriosis.... Agent: Darby & Darby P.C.

20100113500 - Orally bioavailable products of (+)-3-hydroxymorphinan for parkinson's disease prevention or treatment: The present invention is directed to a novel prodrug of (+)-3-hydroxymorphinan compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, and its use for preventing or treating Parkinson's disease.... Agent: Sughrue Mion, PLLC

20100113501 - Ophthalmic composition comprising ascomycin: This invention relates to topical ophthalmic compositions comprising an ascomycin e.g. for the treatment of inflammatory diseases such as blepharitis.... Agent: Novartis Corporate Intellectual Property

20100113503 - Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100113502 - Novel tetrahydro-1h-pyrido[4,3-b] indole derivatives as cb1 receptor ligands: Compounds of formulae I, or pharmaceutically acceptable salts thereof: wherein R1, R2 and R3 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100113504 - Amide compounds and their use as antitumor agents: The present invention relates to a compound of Formula (I), its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemate, as well as pharmaceutically acceptable salts thereof, wherein R is selected from CONHOH, CONHCH2SH, CONHCH2SCOCH3, SH, SCOCH3, SCH3, N(OH)COH, COCONHCH3 and... Agent: Lucas & Mercanti, LLP

20100113505 - Amino-naphthyridine derivatives: The present invention relates to new compounds having an amino-naphthyridine group. In particular, the present invention relates to new compounds, its stereoisomers and pharmaceutically acceptable salts or solvates thereof having a first unit (moiety) selected from the group of a phenyl derivative, a biphenyl derivative or a diphenyl alkane derivative... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20100113506 - Composition for preventing or treating thrombus- or embolus- associated disease: Provided is a composition for the prevention or treatment of a thrombus- or embolus-associated disease, which comprises, as active ingredients to be applied in combination, at least one selected from the group consisting of clopidogrel and its pharmaceutically acceptable salts and at least one selected from the group consisting of... Agent: Birch Stewart Kolasch & Birch

20100113507 - 3-tetrazolyl indazoles, 3-tetrazolyl pyrazolopyridines, and use thereof: The present application relates to novel 3-tetrazolylindazole and 3-tetrazolylpyrazolo[3,4-b]-pyridine derivatives, processes for their preparation, their use alone or in combination for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20100113508 - Modulators of cystic fibrosis transmembrane conductance regulator: The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100113509 - Modulators of cystic fibrosis transmembrane conductance regulator: The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100113510 - Quinuclidinol derivatives as muscarinic receptor antagonists: The invention provides compounds of formula (I) wherein R5 is a group of formula (II) or (III) and R1, R2, R3, R4, R6, a, b, Z, Y and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions,... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100113512 - Method of treatment using novel antagonists or inverse agonists at opioid receptors: A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100113511 - Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors: Provided are monoquaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.... Agent: Crowell & Moring LLP Intellectual Property Group

20100113513 - Quinoline derivatives as fungicides: Compounds of the general formula (I) wherein the substituents are as defined in claim 1, are useful as fungicides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100113514 - Fused heterocyclic compounds as ion channel modulators: m

20100113515 - Pten inhibitor or maxi-k channels opener: wherein R is cycloalkyl, A is lower alkylene, and the bond between 3- and 4-positions of the carbostyril nucleus is single bond or double bond, or a salt thereof, which is useful as a medicament for promotion of the survival of normal cells, brain cells, heart cells, and skin, and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100113516 - Quinolynylmethylimidizoles as therapeutic agents: Disclosed herein is a compound of the formula (I):(I). Therapeutic methods, compositions and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20100113517 - Method for the treatment of fabry disease using pharmacological chaperones: The present invention provides a method treating a patient with Fabry disease by determining whether there is an improvement of a surrogate marker that is associated with Fabry disease following administration of a specific pharmacological chaperone of α-galactosidase A. The method includes administering an effective amount of 1-deoxygalactonojirimycn to the... Agent: Hoffmann & Baron, LLP

20100113518 - Methods of using anti-inflammatory compounds: The invention relates to the use of 3-(2′,2′-dimethylpropanoylamino)-tetrahydropyridin-2-one for preparing a medicament intended to prevent or treat inflammatory disorders.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100113519 - 1,5-dideoxy-1,5-imino-d-glucitol compounds: 1,5-Dideoxy-1,5-imino-D-glucitol compounds as shown in the specification. Also disclosed is a method of treating a hexosaminidase-associated disease.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100113520 - Kinase knockdown via electrophilically enhanced inhibitors: Provided herein are electrophilically enhanced kinase inhibitors. Also provided herein are methods of making and utilizing the same.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100113521 - Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-): The present invention relates to pharmaceutical compositions comprising the NK1 receptor antagonist [2-Methoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-(2S-phenyl-piperidin-3S-yl)-amine, or a pharmaceutically acceptable salt or solvate thereof, and a sodium channel blocker, as a combined preparation for simultaneous or sequential administration and to the use of such compositions in the treatment of certain disorders, including epilepsy,... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100113522 - Compounds for the modulation of ppargamma activity: Modulators of PPARγ activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.... Agent: Jones Day

20100113523 - Tryptase enzyme inhibiting aminopyridines: Disclosed herein are novel compounds and pharmaceutical compositions comprising these compounds. In some embodiments, the compounds are inhibitors of the tryptase enzyme and are useful for treating allergic rhinitis, asthma, vascular injury (e.g., restenosis and atherosclerosis), inflammatory bowel disease, arthritis, psoriasis, anaphylaxis, wounds, infections, and other allergy and inflammatory related... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100113527 - Crystalline forms of dexlansoprazole: Provided are crystalline forms of dexLansoprazole, as well as processes for the preparation thereof.... Agent: Kenyon & Kenyon LLP

20100113528 - Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists: o

20100113525 - Pest control composition: Disclosed is a pest control composition comprising at least one pyripyropene derivative of formula (I) or agriculturally and horticulturally acceptable salt thereof and at least one other pest control agent as active ingredients. The combined use of the two ingredients can provide a better insecticidal effect.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100113526 - Process for the preparation of esomeprazole magnesium dihydrate: A process for preparing Form A of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium dihydrate, processes for preparing various intermediates useful in the preparation of Form A of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium dihydrate and a novel polymorphic Form II of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]thio]-1H-benzimidazole.... Agent: Conley Rose, P.C.

20100113524 - Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety: The compounds of the formulas (I), (II), (III) and (IV), where the symbols are as defined in the specification are prodrugs of proton pump inhibitors. The R4 group includes at least one acidic group or its pharmaceutically acceptable salt, and the compound having the R4 group have improved aqueous solubility,... Agent: Gabor L Szekeres Law Office Of Gabor L Szekeres

20100113529 - Dosage regimen for comt inhibitors: The invention relates to the use of an oxodiazolyl compound (I) for the preparation of a medicament for the prevention or treatment of central and peripheral nervous system associated disorders, wherein said medicament is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day... Agent: Foley & Lardner LLP

20100113530 - S1p lyase inhibitors for the treatment of cerebral malaria: Methods and compositions for treating, managing, and/or preventing cerebral malaria are disclosed.... Agent: Lexicon Pharmaceuticals, Inc.

20100113532 - Modulators of the glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof: including a stereoisomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Q is selected from N, O, and S; Y is aryl or heteroaryl; Z is H, C2-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, or alkoxy; and A, B, R, Ra, Rb, Rc and Rd... Agent: Louis J. Wille Bristol-myers Squibb Company

20100113531 - Thiazolidine derivatives as orexin receptor antagonists: The invention relates to novel thiazolidine derivatives of the formula (I) wherein A and R1 are as described in the description and their use as medicaments, especially as orexin receptor antagonists.... Agent: Hoxie & Associates LLC

20100113533 - Polymorph ii of 4-[4-(amino)-3- fluorophenoxy]-n-methylpyridine-2-carboxamide: The present invention relates to the polymorph II of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders.... Agent: Millen, White, Zelano & Branigan, P.C.

20100113534 - Pharmaceutical compositions and methods for producing low impurity concentrations of the same: A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.... Agent: Gibbons P.C.

20100113535 - Treatment of presbyopia with alpha- picolinic acid and its analogs: Compositions and methods for inhibiting the growth of lens epithelial cells are provided. The compositions provided include a chelating agent in an amount sufficient for inhibiting the growth of lens epithelial cells. The compositions and methods provided may also be used for the treatment of disorders of the eye, especially... Agent: Blank Rome LLP

20100113536 - haloalkylsulfone substituted compounds useful for treating obesity and diabetes: The present invention relates to novel compounds of formula [I], wherein R1 represents heteroaryl, at least one substituent among R5, R6 and R7 represent —SR12, —S(O)R12 or —S(O)2R12 and the remaining substituents are as defined in the claims, that act as chemical uncouplers. Compounds of the invention are useful inter... Agent: High Point Pharmaceuticals, LLC

20100113537 - Antimicrobial fiber and its production method, and antimicrobial fiber product comprising the antimicrobial fiber, its production method and regeneration method: An antimicrobial fiber bearing an anionic functional group, and a method of producing it wherein at least a part of the anionic functional group forms a quaternary ammonium salt and at least another part thereof forms an antimicrobial metal salt. The quaternary ammonium salt is preferably a cetylpyridinium salt, and... Agent: Young & Thompson

20100113539 - Compounds for treating ophthalmic diseases and disorders: Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100113538 - N-hydroxy-4- benzamidine 2 ethansulfonic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same: N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 ethansulfonic acid salt, a process for the preparation thereof, a pharmaceutical composition for preventing and treating osteoporosis, bone fractures or allergic inflammatory diseases, comprising the same, and an oral formulation for preventing and treating osteoporosis, bone fractures or allergic inflammatory diseases, comprising the same are described.... Agent: Arent Fox LLP

20100113540 - Azole and thiazole derivatives and their use: Compounds of formula (I) are useful in the treatment of diseases where enhanced M3 receptor activation is implicated, such as respiratory tract diseases: wherein (i) R1 is C1-C6-alkyl or hydrogen; and R2 is hydrogen or a group —R7, —Z—Y—R7, —Z—NR9R10; —Z—CO—NR9R10, —Z—NR9—[AE11]C(O)O—R7, or —Z—C(O)—R7; and R3 is a lone pair,... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100113541 - Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol: The present invention is directed to monohydrate and anhydrate crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.... Agent: Pepper Hamilton LLP/wyeth LLC

20100113543 - Crystalline complexes of agriculturally active organic compounds: The present invention relates to crystalline complexes comprising at least one agriculturally active organic compound A having at least one functional moiety which is capable as serving as a hydrogen acceptor in a hydrogen bond and thiophanate-methyl.... Agent: Brinks, Hofer, Gilson & Lione

20100113542 - Triazole derivative as an hsp 90 inhibitor: 5-[4-(2-Methylphenyl)-3-hydroxy-4H-1,2,4-triazol-5-yl]-2,4-dihydroxy-N-methyl-N-butylbenzamide is an HSP90 inhibitor and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.... Agent: Millen, White, Zelano & Branigan, P.C.

20100113544 - Suppressant for cerebral infarction attributed to long-time ischemia: An object of the present invention is to provide a cerebral infarction suppressant which is effective for brain tissue necrosis after long-time ischemia as in actual cerebral infarction and has fewer side effects. The cerebral infarction suppressant of the present invention is characterized in that histidine is contained and the... Agent: Fitch, Even, Tabin & Flannery

20100113545 - Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders: wherein R1, R2, R3, R4, R5, R6, R15, R7, R8 and m are as defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100113546 - Imidazol-4-one and imidazole-4-thione compounds: e

20100113547 - Novel imidazolidine compounds as androgen receptor modulators: wherein X, R1, R2a, R2b, R2c, R3a R3b, R4a, R4b, R4c, and m1 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cachexia,... Agent: Klauber & Jackson

20100113548 - Antagonists of bitter taste receptors and uses thereof: The present invention relates to antagonists of the human bitter-taste receptors hTAS2R38. The invention also relates to methods for identifying further molecules that suppress hTAS2R38 mediated bitter taste transduction or bitter taste response and uses thereof.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100113550 - New crystal forms: Polymorphs of (R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione hydrochloride and methods of their preparation.... Agent: Conley Rose, P.C.

20100113549 - Pyrrolidine compounds: The present invention relates to a process for the preparation of a pyrrolidone compound of the formula (I): where R1 is substituted or unsubstituted alkyl, alkenyl, or alkynyl, or an aromatic or non-aromatic cyclic or heterocyclic structure, R2 is substituted or unsubstituted alkyl or cycloalkyl, and each P is independently... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20100113551 - Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases: The invention provides a composition comprising (S) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, wherein the composition is either substantially free of (R) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol or the composition contains a mixture of the (S) and (R) enantiomers in which the (S) enantiomer predominates. Also provided are processes for the preparation of the (S) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, novel process intermediates... Agent: Heslin Rothenberg Farley & Mesiti PC

20100113552 - Fungicidal composition: A composition comprising (i) a compound of Formula (I), wherein R1 is CH3, CHF2 or CF3; R2 is H, F or Cl; X is —CH═CH— or —S—; and R3 is bicyclopropyl, 1,3-dimethylbutyl or 1,3,3-trimethylbutyl; (ii) cyprodinil and (iii) an unsaturated C18-fatty acid selected from oleic acid, linoleic acid and linolenic... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100113553 - Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom: Methods and therapeutic strategies utilizing proteinacious channels in lipid membranes of mammalian cells. The methods entail administering a pharmaceutical to a lipid membrane of a mammalian cell, and then determining the effect of the pharmaceutical on the electrophysiology of at least one vascular proteinacious channel of the lipid membrane, wherein... Agent: Hartman & Hartman, P.C.

20100113554 - Manufacture and products thereof of photosensitizing nanomaterials and their use in photodynamic treatment: A method for the manufacture of a photosensitizing nanomaterial (40) and the products thereof are disclosed. The method for the treatment of a biological target (50) is disclosed. The photosensitizing nanomaterial (40) comprises a metal complex tetrapyrrole derivative (10). The metal complex tetrapyrrole derivative (10) is attached by an axial... Agent: Sylke Law Offices, LLC

20100113555 - Modulators of atp-binding cassette transporters: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100113556 - Novel crystal forms of pyrrolylheptanoic acid derivatives: The present invention provides novel crystalline forms D1 and D2 of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemicalcium salt, and hydrates thereof. The crystalline forms D1 and D2 have X-ray powder diffraction peaks described in FIGS. 1 and 3, respectively. Further, the present invention provides processes for preparing the crystalline forms and pharmaceutical compositions... Agent: The Nath Law Group

20100113579 - Prodrugs of excitatory amino acids: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.... Agent: Eli Lilly & Company

20100113580 - Combination therapies for the treatment of obesity: Described are pharmaceutical compositions comprising bupropion, metformin, orlistat, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100113581 - Combination therapies for the treatment of obesity: Described are pharmaceutical compositions comprising diethylpropion, metformin, orlistat, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100113582 - Methods and compositions for treating hiv infections: Described herein are compounds and compositions that are useful in the treatment of HIV, AIDS, and AIDS-related diseases. In addition, compounds are described herein that are capable of inhibiting the dimerization of HIV proteases.... Agent: Barnes & Thornburg LLP

20100113583 - Combination therapies for the treatment of obesity: Described are pharmaceutical compositions comprising bupropion, metformin, topiramate, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100113585 - Compositions and methods for treating cancer: Compounds of formulas I-IV: (I), (II), (III) (IV), wherein: R1 and R4-R23 are independently selected from H and 1-3 carbon lower alkyl; and R2 and R3 are independently selected from H, 1-3 carbon lower O II alkyl, and —C—Ra, wherein Ra is 1-3 carbon lower alkyl. Pharmaceutical compositions, which include... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20100113584 - Novel use of (-)-epigallocatechin gallate: Use of (−)-epigallocatechin gallate and/or one or more of its derivatives for increasing the desire, willingness and/or motivation of animals (including humans), especially mammals, to exercise, to perform and/or to run, especially to perform endurance exercise and furthermore to accelerate training success.... Agent: Nixon & Vanderhye, PC

20100113586 - Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms: Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with pre menopause, menopause, and/or post menopause are described herein. These select phytoestrogen formulations are composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to... Agent: Pabst Patent Group LLP

20100113587 - Abscissic acid and derivatives thereof for the treatment of diseases: The present invention relates generally to the fields of molecular biology and pharmacology. More particularly, it concerns the use of abscissic acid to treat various diseases, including neurodegenerative diseases and neuromuscular diseases.... Agent: Attn: Barbara Krebs Yuill Dunlap Codding & Rogers, P.C.

20100113588 - Composition and methods for the protection of hair from treated pool water: Compositions for treating hair are disclosed. Methods of making and using compositions for treating hair are also disclosed.... Agent: Withers & Keys, LLC

20100113589 - Deuterated darunavir: This invention relates to novel compounds that are hydroxyethylamino sulfonamide derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel hydroxyethylamino sulfonamide derivatives that are derivatives of darunavir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100113590 - Adam inhibitor: Disclosed is an ADAM inhibitor which enables to prevent or improve conditions caused by increase in ADAM activity. Specifically disclosed is an ascorbic acid derivative represented by the general formula (1) below or a salt thereof. [chemical formula 1] (1), wherein R represents a linear or branched alkyl group having... Agent: Darby & Darby P.C.

20100113591 - Methods and compositions for treating amyloid-related diseases: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.... Agent: Mccarter & English/ Neurochem

20100113592 - Unsymmetrical aromatic ether diacids and absorbable polymers therefrom: t

20100113594 - Pesticidal composition and method for controlling harmful insects: A pesticidal composition containing: 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate, a saturated hydrocarbon having an initial boiling point of 150 C or higher and a 95%-distillation temperature of 300 C or lower, and at least one alkyl carboxylate ester selected from the group consisting of the following esters (i) to (iii): (i) alkyl alkylcarboxylate... Agent: Birch Stewart Kolasch & Birch

20100113593 - Topical fungicidal agents for treating nail disorders: The invention relates to water-free, topically applicable agents for treating, nail problems caused by mycoses, and for nail care, said agents containing at least one C1-C4 alkyl ester of lactic acid, malic acid, tartaric acid or citric acid and physiologically compatible auxiliary substances. The agents according to the invention can... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100113595 - Treatment of neurodegenerative conditions: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic... Agent: Nixon & Vanderhye, PC

20100113596 - Method for inhibiting liver fibrosis via retinoic acid derivative: Transforming growth factor-beta1 (TGF-β1) mediates expression of collagen 1A2 (Col 1A2) gene via a synergistic cooperation between Smad2/Smad3 and Sp1, both act on the Col 1A2 gene promoter. The present invention discloses a method for inhibiting liver fibrosis via a retinoic acid derivative primarily extracted from the mycelia of Phlellinus... Agent: Rosenberg, Klein & Lee

20100113597 - Pharmaceutical composition for prevention of progress of intestinal constriction associated with crohn's disease: The present invention provides an oral pharmaceutical composition for inhibiting the progression of intestinal stricture associated with Crohn's disease. That is, the present invention relates to a pharmaceutical composition for inhibiting the progression of intestinal stricture associated with Crohn's disease which comprises as an active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid (generic name:... Agent: Sughrue Mion, PLLC

20100113598 - High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders: The present invention provides for a method of treating OCD or an Obsessive-Compulsive Spectrum Disorder (OCSD), such as BDD or ADHD, using a high-dose glycine treatment.... Agent: Greenberg Traurig, LLP

20100113599 - Amphipathic carboxylates for the treatment of immune-related disorders: The present invention relates to the use of at least one long-chain optionally-substituted amphipatic carboxylates (known as MEDICA drugs) or any salt, ester or amid thereof or any combination or mixture thereof, for the treatment and prevention of immune-related disorders, particularly, inflammatory conditions. More specifically, the invention relates to particular... Agent: Buchanan, Ingersoll & Rooney PC

20100113600 - Anti-cancer agents and androgen inhibition activity compound: A qualitative 3D pharmacophore model (a common feature based model or Catalyst HipHop algorithm) developed from well-known natural product androgen receptor down-regulating agents (ARDAs). The 3D pharmacophore model is used as a template in virtual screening compounds for new ARDAs. ARDA compounds and compounds that strongly inhibit the growth of... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100113601 - Method for decreasing sebum production: The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin.... Agent: Mcdermott Will & Emery LLP

20100113602 - Use of histone deacetylase inhibitors for the treatment of central nervous system metastases: Disclosed is a method of treating a localized carcinoma central nervous system (CNS) metastasis of extra-CNS origin, the method comprising systemically administering an effective amount of a histone deacetylase (HDAC) inhibitor (HDI) to a subject in need of treatment for the localized carcinoma CNS metastasis of extra-CNS origin. The HDI... Agent: Leydig, Voit & Mayer, Ltd.

20100113603 - Combination therapies for the treatment of obesity: Described are pharmaceutical compositions comprising bupropion, metformin, phentermine, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100113604 - Combination therapies for the treatment of obesity: Described are pharmaceutical compositions comprising metformin, diethylpropion, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100113605 - Methods, compositions and uses thereof: The invention relates to a method for identifying a candidate compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission in the central nervous system, the method comprising the following steps: (a) providing a compound to be tested; (b) testing the ability of the compound to bind... Agent: Fennemore Craig

20100113606 - Aminopropanol modulators of beta-1 adrenergic receptor: The present invention relates to new aminopropanol modulators of beta-1 adrenergic receptor activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100113607 - Pharmaceutical compositions: A method for the topical treatment of nail diseases, e.g. onychomycosis, after preparation of the infected nail with a laser beam.... Agent: Novartis Corporate Intellectual Property

20100113608 - Tryptase enzyme inhibiting aminothiophenols: Disclosed herein are novel compounds and pharmaceutical compositions comprising these compounds. In some embodiments, the compounds are inhibitors of the tryptase enzyme and are useful for treating allergic rhinitis, asthma, vascular injury (e.g., restenosis and atherosclerosis), inflammatory bowel disease, arthritis, psoriasis, anaphylaxis, wounds, infections, and other allergy and inflammatory related... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100113609 - Methods and compositions for malaria prophylaxis: A composition for preventing malaria infection including a protease inhibitor. A pharmaceutical composition for preventing malaria infection including a protease inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria... Agent: Kohn & Associates, PLLC

20100113610 - Methods for controlling inflammatory and immunological diseases: The present invention provides methods for generating mucosal tissue homing immunosuppressive T-cells comprising treating naïve T-cells with retinoids and/or retinoid agonists. Methods are also provided for treating a mammal having an inflammatory or immunological disease by administering a therapeutically effective dose of retinoids and/or retinoid agonists. Additional methods are also... Agent: Bose Mckinney & Evans LLP

20100113611 - Novel use of hydroxytyrosol: The invention relates to the use of hydroxytyrosol for inducing or enhancing cartilage repair or cartilage regeneration. Furthermore, the invention relates to nutraceutical and pharmaceutical compositions comprising hydroxytyrosol for regeneration and repair of cartilage injuries in joints, in particular of traumatic cartilage injuries.... Agent: Nixon & Vanderhye, PC

20100113612 - Novel use of hydroxytyrosol and olive extracts/concentrate containing it: The present invention is directed to the use of (a composition comprising) hydroxytyrosol as life prolonging agent. The composition, to which the present invention is also directed, does essentially not comprise resveratrol and is preferably administered orally to animals. The present invention is further directed to a life prolonging method.... Agent: Nixon & Vanderhye, PC

20100113613 - cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation: The invention provides formulations, dosage forms, and treatments comprising cyclohexane polyalcohol compounds that provide beneficial pharmacokinetic profiles in the treatment of a disorder and/or disease including a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence. In aspects of the invention, a dosage form is provided... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100113614 - Compositions and methods for delivery of frozen particle adhesives: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least... Agent: Searete LLC Clarence T. Tegreene

20100113615 - Compositions and methods for delivery of frozen particle adhesives: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least... Agent: Searete LLC Clarence T. Tegreene

20100113616 - Inhibition of discoloration by washing and cleaning agents and/or cosmetic agents: Method of inhibiting discoloration in agents by incorporating iodide salt(s), preferably calcium, potassium and/or sodium iodides into the formulation of those agents. The method is particularly suited for agents comprising vanillin and/or vanillin derivatives, wherein vanillin and/or vanillin derivatives are components of a fragrance mixture and the agents are washing... Agent: Henkel Corporation

20100113617 - Method for implementing active ingredients in order to protect them and optimize their delivery method: The invention pertains to a new method for formulating pharmaceutical active ingredients in such a way as to protect them when ingested orally, and to allow for the controlling of the release of the active ingredient in the intestine. It relies upon the use of thickening acrylic emulsions with a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100113618 - Pseudo-thermosetting neutralized chitosan composition forming a hydrogel and a process for producing the same: The composition disclosed is a pseudo-thermosetting neutralized chitosan composition, neutralized with a hydroxylated base, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C. Said composition contains a homogeneously reacetylated chitosan derived from a chitosan having a deacetylation degree of 80-90%, having a molecular weight of not smaller... Agent: Harness, Dickey & Pierce, P.L.C

20100113619 - High-amylose sodium carboxymethyl starch sustained release excipient and process for preparing the same: A process for obtaining a spray-dried high amylose sodium carboxymethyl starch comprising a major fraction of amorphous form and optionally a minor fraction of crystalline V form, is provided. The process comprises providing an amorphous pregelatinized high amylose sodium carboxymethyl starch (HASCA); dispersing the amorphous pregelatinized HASCA in a solution... Agent: The Nath Law Group

20100113620 - Enteric pharmaceutical capsules: This invention pertains generally to the field of hard enteric capsules, and more particularly, to capsules consisting of (a) a film-forming, water-soluble polymer; (b) an acid-insoluble polymer; (c) a gelatinising agent; (d) an auxiliary for gelation; (e) at least one plasticiser; (f) minor ingredients, including, optionally, a colouring agent and... Agent: Michael Best & Friedrich LLP

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.68396 seconds

PATENT INFO